<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_nxgYZsJ">Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review</title>
				<funder>
					<orgName type="full">American Diabetes Association</orgName>
					<orgName type="abbreviated">ADA</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000041</idno>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">Â© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals .org/content/license.</p>
				</availability>
				<date type="published" when="2025-08-14">14 August 2025</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Ping</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention , Atlanta , GA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xilin</forename><surname>Zhou</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention , Atlanta , GA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karen</forename><forename type="middle">R</forename><surname>Siegel</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention , Atlanta , GA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Boon</forename><forename type="middle">Peng</forename><surname>Ng</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> College of Nursing and Disability, Aging and Technology Cluster , University of Central Florida , Orlando , FL</note>
								<orgName type="department">College of Nursing and Disability, Aging and Technology Cluster</orgName>
								<orgName type="institution">University of Central Florida</orgName>
								<address>
									<settlement>Orlando</settlement>
									<region>FL</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shawn</forename><surname>Jawanda</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention , Atlanta , GA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Oak Ridge Institute for Science and Education , Oak Ridge , TN</note>
								<orgName type="institution">Oak Ridge Institute for Science and Education</orgName>
								<address>
									<settlement>Oak Ridge</settlement>
									<region>TN</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Krista</forename><forename type="middle">K</forename><surname>Proia</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention , Atlanta , GA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xuanping</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention , Atlanta , GA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ann</forename><forename type="middle">L</forename><surname>Albright</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Division of Diabetes Translation , Centers for Disease Control and Prevention , Atlanta , GA</note>
								<orgName type="department" key="dep1">Division of Diabetes Translation</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_57ygGh5">Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2025-08-14">14 August 2025</date>
						</imprint>
					</monogr>
					<idno type="MD5">991499AE0A63669C6D15DE9F6A681527</idno>
					<idno type="DOI">10.2337/dci20-0018</idno>
					<note type="submission">Received 23 March 2020 and accepted 3 April 2020</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zY2hjfn">OBJECTIVE</head><p xml:id="_DTMpaAx"><s xml:id="_KNnsbke">We conducted a systematic review of studies evaluating the cost-effectiveness (CE) of interventions to prevent type 2 diabetes (T2D) among high-risk individuals and whole populations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_H59J773">RESEARCH DESIGN AND METHODS</head><p xml:id="_8vna384"><s xml:id="_Hq99UKb">Interventions targeting high-risk individuals are those that identify people at high risk of developing T2D and then treat them with either lifestyle or metformin interventions.</s><s xml:id="_ZE2NHAd">Population-based prevention strategies are those that focus on the whole population regardless of the level of risk, creating public health impact through policy implementation, campaigns, and other environmental strategies.</s><s xml:id="_s5bAQXZ">We systematically searched seven electronic databases for studies published in English between 2008 and 2017.</s><s xml:id="_4CpCxPb">We grouped lifestyle interventions targeting highrisk individuals by delivery method and personnel type.</s><s xml:id="_c9xqDhb">We used the median incremental cost-effectiveness ratio (ICER), measured in cost per quality-adjusted life year (QALY) or cost saved to measure the CE of interventions.</s><s xml:id="_MfncKZc">We used the $50,000/QALY threshold to determine whether an intervention was cost-effective or not.</s><s xml:id="_c6x9bjZ">ICERs are reported in 2017 U.S. dollars.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Hbgd6Tq">RESULTS</head><p xml:id="_Wv9E2Da"><s xml:id="_2u9sG4q">Our review included 39 studies: 28 on interventions targeting high-risk individuals and 11 targeting whole populations.</s><s xml:id="_sKmgNhn">Both lifestyle and metformin interventions in high-risk individuals were cost-effective from a health care system or a societal perspective, with median ICERs of $12,510/QALY and $17,089/QALY, respectively, compared with no intervention.</s><s xml:id="_vMzsNYA">Among lifestyle interventions, those that followed a Diabetes Prevention Program (DPP) curriculum had a median ICER of $6,212/QALY, while those that did not follow a DPP curriculum had a median ICER of $13,228/QALY.</s><s xml:id="_zYDrJ9v">Compared with lifestyle interventions delivered one-on-one or by a health professional, those offered in a group setting or provided by a combination of health professionals and lay health workers had lower ICERs.</s><s xml:id="_xFRQSvY">Among populationbased interventions, taxing sugar-sweetened beverages was cost-saving from both the health care system and governmental perspectives.</s><s xml:id="_WtDFcFp">Evaluations of other population-based interventionsdincluding fruit and vegetable subsidies, community-based education programs, and modifications to the built environmentd showed inconsistent results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_6zkwXwN">CONCLUSIONS</head><p xml:id="_xskagpa"><s xml:id="_MewrS7S">Most of the T2D prevention interventions included in our review were found to be either cost-effective or cost-saving.</s><s xml:id="_J2E5KrS">Our findings may help decision makers set priorities and allocate resources for T2D prevention in real-world settings.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="21" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="22" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="23" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
		<surface n="24" ulx="0.0" uly="0.0" lrx="593.972" lry="782.986"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_h3f8CfE"><p xml:id="_uSvwCzm"><s xml:id="_Q5a4KEw">Diabetes is a major global health issue.</s><s xml:id="_PuYwdmx">In 2019, there were an estimated 463 million adults aged 20-79 years with diabetes globally (;9.3% of the population in this age-group), a figure that is projected to increase to 700 million by 2045 <ref type="bibr" target="#b0">(1)</ref>.</s><s xml:id="_dr7PvXc">Health care expenditures attributable to diabetes were estimated at $1.3 trillion in 2015 <ref type="bibr" target="#b1">(2)</ref>.</s><s xml:id="_BYTBZUx">Fortunately, type 2 diabetes (T2D), which accounts for 90-95% of the disease burden (3), can be prevented or delayed through nutrition and lifestyle changes as well as through pharmacologic interventions <ref type="bibr" target="#b3">(4)</ref>.</s></p><p xml:id="_v7fncg9"><s xml:id="_6VjeRsC">Approaches to prevent T2D fall under two categories: targeting individuals at high risk for developing T2D (high-risk approaches) and targeting the whole population regardless of the level of risk (population-based approaches).</s><s xml:id="_aWVraqs">In general, high-risk individuals are those who have prediabetes (a health condition with a blood glucose level that is higher than normal but does not reach the level of diagnosed T2D) or who have risk factors for developing T2D, such as having a family history of T2D, being overweight or obese, being physically inactive, being 45 years old or older, or being a woman with a history of gestational diabetes mellitus <ref type="bibr" target="#b4">(5)</ref>.</s><s xml:id="_Hb4sVjq">Interventions targeting high-risk individuals include screening for T2D in clinics and communities and providing lifestyle or pharmacologic interventions.</s><s xml:id="_wDMZPbC">On the other hand, population-based approaches aim to impact public health through policy implementation, campaigns, and other environmental change strategies.</s><s xml:id="_pT6Z29R">For example, imposing taxes on sugar-sweetened beverages (SSBs) has been proposed as a population-based approach to combat T2D and cardiovascular disease by the World Health Organization <ref type="bibr" target="#b5">(6)</ref>.</s><s xml:id="_gZfm4Gj">Epidemiological evidence on the association between added sugars and T2D incidence and implementation experiences from Mexico and selected cities in the U.S. (Berkeley, for example) have led decision makers to explore the feasibility and effectiveness of scaling up such policies <ref type="bibr" target="#b6">(7,</ref><ref type="bibr" target="#b7">8)</ref>.</s><s xml:id="_XqKAMqD">Some experts suggest that the goal of reducing the number of new cases of T2D in the U.S. and worldwide is likely best achieved through approaches that combine both high-risk and population-based approaches <ref type="bibr" target="#b8">(9,</ref><ref type="bibr" target="#b9">10)</ref>.</s></p><p xml:id="_pagzkgu"><s xml:id="_sja5wpA">T2D prevention approaches, whether high-risk or population-based, vary in terms of intervention effectiveness and cost.</s><s xml:id="_dYVF8F9">However, their cost-effectiveness (CE) has not been evaluated comprehensively or systematically.</s><s xml:id="_KtnrDjJ">Most literature reviews to date have assessed the efficacy of T2D prevention approaches only without considering their CE or with focus on a single strategy <ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref>.</s><s xml:id="_WPgShh4">For example, one review and meta-analysis focused on nutrition education and examined the cost and CE of using diet modification as a T2D preventive intervention <ref type="bibr" target="#b15">(16)</ref>.</s><s xml:id="_xcveZuv">Another systematic review measured the CE of T2D high-risk prevention approaches but focused on lifestyle interventions only <ref type="bibr" target="#b16">(17)</ref>.</s><s xml:id="_MYSxuhy">A recent study reviewed the CE of both lifestyle and metformin for T2D prevention among high-risk individuals but did not include population-based approaches <ref type="bibr" target="#b17">(18)</ref>.</s><s xml:id="_EPVydHJ">Another review evaluated both high-risk and population-based approaches (19); however, it did not examine key features of lifestyle interventionsdsuch as intervention delivery mode and formatd that might affect the CE outcome, and it only included fiscal policies among the population-based approaches.</s><s xml:id="_Ce3RsRC">In addition, many new studies on the CE of T2D prevention interventions that have been published in recent years need to be evaluated in a review.</s></p><p xml:id="_Rp68FA3"><s xml:id="_ZQc65HH">Here, we systematically review the CE of both high-risk and population-based approaches for T2D prevention.</s><s xml:id="_7Fh8PgB">The goal is twofold: 1) to update evidence on high-risk approaches implemented in real-world settings, including whether to screen, whom to screen, and which formats are best for delivering lifestyle interventions (in-person vs. virtual, one-onone vs. group, etc.) and 2) to synthesize evidence on population-based prevention strategies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ngeApMb">RESEARCH DESIGN AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ybgCe6Z">Literature Search</head><p xml:id="_3GWMU5S"><s xml:id="_xpkBFvr">We searched the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane databases, Excerpta Medica (EMBASE), Medical Literature Analysis and Retrieval System Online (MedlinePlus), PsycINFO, Scopus, and Sociological Abstracts (Soc Abs) to identify original economic evaluations of approaches to prevent T2D published in English from January 2008 to July 2017.</s><s xml:id="_zgs2vrT">Search keywords included 1) diabetes, impaired glucose tolerance, and insulin resistance; 2) expenditure, health care cost, and cost of illness; 3) quality-adjusted life year (QALY), disabilityadjusted life year (DALY), and incidence of diabetes; and 4) cost-effectiveness analysis (CEA), cost-utility analysis, cost-benefit analysis, and economic evaluation <ref type="bibr" target="#b19">(20)</ref>.</s><s xml:id="_AeRCZVf">In addition to searching the seven databases above, we manually screened the reference lists of all included studies as well as the table of contents of major diabetes journals (Diabetes Care, The Lancet Diabetes &amp; Endocrinology, Diabetologia, and Diabetes Research and Clinical Practice) during the search period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_wEPmesF">Study Design for Reviewing Interventions Targeting High-risk Individuals</head><p xml:id="_HPtyYGx"><s xml:id="_s74myya">Following the Cochrane Collaboration's protocol for systematic reviews <ref type="bibr" target="#b20">(21)</ref>, two people independently reviewed each study for inclusion/exclusion in our review, quality assessment, and data abstraction.</s><s xml:id="_6HcjzUp">We focused on three types of economic evaluations of high-risk approaches to T2D prevention: CE, costutility, and cost-benefit analyses.</s><s xml:id="_cp74cGn">We included studies that reported quantitative measures for the CE outcomes.</s><s xml:id="_phRqB6F">The outcome was the incremental costeffectiveness ratio (ICER), which is in the form of cost-per-additional QALY gained or cost-per-additional DALY averted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mqVSdyA">Quality Assessment of the Included Studies</head><p xml:id="_w8Hmj3C"><s xml:id="_nQnE667">To assess the quality of included studies, we used a tool based on The BMJ authors' guide for economic studies <ref type="bibr" target="#b21">(22)</ref>, which was used previously <ref type="bibr" target="#b19">(20)</ref>.</s><s xml:id="_QkRzcyM">In brief, the tool assesses each study based on 13 attributes: sources of cost data, sources of benefit data, categories of cost data, categories of benefit data, analytical time horizons, study perspectives, model descriptions, structure diagrams, currency and year of the costs, discounting factor for costs, discounting factor for benefits, ICERs, and sensitivity analyses.</s><s xml:id="_3PcY57K">Each attribute was given one pointdan equal weightdif the study clearly stated it.</s><s xml:id="_3CeTKQn">We included studies with a quality score of seven and above <ref type="bibr" target="#b19">(20)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YrNx3pK">Data Abstraction and Cost Adjustment</head><p xml:id="_KBcHVBh"><s xml:id="_698HWGR">We abstracted the following information from each study: publication information, study objective, prevention approach, comparison, target population, delivery method, provider, analytical time horizon, study method, perspective of the evaluation, and results.</s><s xml:id="_ZCHPEDr">We adjusted ICERs and costs to 2017 U.S. dollars using the Consumer Price Index <ref type="bibr" target="#b22">(23)</ref>.</s><s xml:id="_bK7Vpnv">For studies conducted in countries other than the U.S., we used the annual exchange rate from the Federal Reserve Bank to convert the foreign currencies into U.S. dollars before adjusting them for inflation <ref type="bibr" target="#b23">(24)</ref>.</s><s xml:id="_wdxRRJN">In rare cases where the study did not report the specific year of currency used to calculate costs, we assumed the costs were calculated 1 year before the publication date.</s><s xml:id="_hbuUyek">Studies were considered cost-effective if the ICER was below the $50,000/QALY threshold <ref type="bibr" target="#b24">(25)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XYrVCAh">Grouping High-risk Approaches to T2D Prevention</head><p xml:id="_emZWccQ"><s xml:id="_Ryrazm9">We grouped high-risk approaches into four categories based on their study objectives: 1) articles focused on deciding whether to screen for prediabetes, 2) articles determining the target population for screening that would generate the optimal CE outcomes, 3) articles evaluating the CE of specific T2D prevention interventions, and 4) articles evaluating the CE of managing gestational diabetes mellitus.</s></p><p xml:id="_kCwAF7V"><s xml:id="_2XYBn9Y">To better understand what features contribute to the CE outcomes of prevention interventions, we examined interventions from the third category above (those evaluating the CE of specific T2D prevention interventions) and summarized the median and range of ICERs for interventions sharing similar features in terms of how the intervention is delivered (i.e., whether delivered one-onone or in a group and whether conducted in-person or via virtual media, such as internet or mobile applications) and by whom (i.e., whether taught by health care providers or lay health workers, such as trained community health workers or diabetes educators).</s><s xml:id="_qVdtYG8">The high-risk approaches included lifestyle interventions (translational Diabetes Prevention Program [DPP] and translational non-DPP) and pharmacologic interventions (metformin).</s><s xml:id="_v2uCTXv">Translational DPPs refer to nutrition and physical activity interventions that follow the DPP curriculum that translated to the real world, such as those provided in the community or primary care setting.</s><s xml:id="_gCWfN4Q">In contrast, translational non-DPPs are lifestyle interventions that do not strictly follow the DPP curriculum.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7r9z7wY">Study Design for Population-Based Interventions</head><p xml:id="_vpAkfzE"><s xml:id="_gBuXSwH">We modified our study protocol to accommodate the methods and results reported in studies on population-based approaches because many of them did not use the standard framework for assessing CE due to a lack of data.</s><s xml:id="_XAQAc7s">For study screening, we included population-based interventions if they reported ICERs or if they compared costs given a certain level of benefits if benefits were measured as T2D cases prevented or QALY due to reduction in diabetes.</s><s xml:id="_tpFdGpv">Consequently, the result of cost-saving (CS) for population-based interventions should be interpreted with caution, as it could refer to a reduction in health costs only rather than savings as measured by ICER, which is a negative incremental cost.</s></p><p xml:id="_387fvvV"><s xml:id="_SXtYcUZ">Quality assessment for populationbased approaches was less restrictive and reduced to nine scoring attributes (the other four pertained to formal CEA and did not apply in these cases): sources of cost data, sources of benefit data, categories of cost data, categories of benefit data, analytical time horizons, study perspectives, model descriptions, currency and year of the costs, and results.</s><s xml:id="_qrvy4XA">Again, we included studies with a quality score of seven and above.</s></p><p xml:id="_kwdaqWt"><s xml:id="_zVXKPXN">For selected studies, we abstracted data on publication information, objective, prevention strategy, comparison, target population, analytic time horizon, study method, the perspective of the evaluation, and results.</s><s xml:id="_F8EABNr">We then grouped population-based approaches into four categories and summarized CE of each one: 1) implementing fiscal policy, 2) implementing a regulation, 3) promoting health by education and information, and 4) changing the built or food environment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_j6JgqdG">RESULTS</head><p xml:id="_2nmE3aH"><s xml:id="_9pcfX8k">Figure <ref type="figure" target="#fig_0">1</ref> shows the 39 studies that met our inclusion criteria: 28 articles on highrisk approaches and 11 articles on population-based approaches.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gsgRv93">High-risk Approaches</head><p xml:id="_DWM9rjU"><s xml:id="_m4XkJDQ">Table <ref type="table" target="#tab_10">1A</ref> shows studies arranged chronologically and then alphabetically by the last name of the first author within each category .</s><s xml:id="_uyb9R8r">Among these studies, the analytic time horizon ranged from 1 year to a lifetime.</s><s xml:id="_JK8F65A">Studies were evaluated from either a societal perspective or a health care perspective.</s><s xml:id="_HsnRkB3">Most studies discounted costs and benefits at 3%.</s><s xml:id="_zvfG9w8">While most of the studies were based on simulation modeling, eight studies assessed prevention strategies using randomized controlled trials.</s><s xml:id="_F4fEHnA">Results indicate that screening for prediabetes and providing interventions, either lifestyle or pharmacologic interventions, is either cost-effective or CS among individuals with a high risk of T2D.</s><s xml:id="_RSdZ2pe">The conclusion held for both the societal and health care perspectives and for shorter or longer time horizons.</s></p><p xml:id="_4anCkGb"><s xml:id="_kxftDp5">Seventeen studies (or study arms) evaluated the CE of specific interventions compared with no intervention (status quo or placebo) from a health care system perspective (Table <ref type="table" target="#tab_11">2</ref>) <ref type="bibr">(35-37, 39,40,42-44,46,49-51)</ref>.</s><s xml:id="_wjTmZNa">Results indicate that all interventions were cost-effective, but the magnitude of the ICERs differed by intervention features.</s><s xml:id="_RH49EVX">Lifestyle interventions were more cost-effective than metformin interventions, regardless of analytical time horizon, delivery method, media, mode, and personnel type.</s><s xml:id="_f2scTHg">Among lifestyle interventions, translational DPP was more cost-effective than translational non-DPP prevention approaches.</s><s xml:id="_jNYMvZa">The median ICER for translational non-DPP was twice as high as that for translational DPP.</s><s xml:id="_kEUytkx">Analytical time horizon also affects CE outcomes; studies evaluated over a longer time horizon have a lower ICER.</s><s xml:id="_q9exZR7">Among lifestyle interventions, in-person interventions had slightly better CE outcomes than virtual interventions.</s><s xml:id="_g2JqtRU">The median ICERs for interventions delivered in groups and for interventions provided by a combination of health professionals and trained lay health workers were less than half of those for the one-on-one interventions or interventions provided by health professionals alone.</s><s xml:id="_YxfS8pW">Population-Based Approaches</s></p><p xml:id="_HgER7Cb"><s xml:id="_jYthv65">Table 1B describes the 11 studies that evaluated 28 population-based approaches to preventing T2D <ref type="bibr" target="#b53">(54)</ref><ref type="bibr" target="#b54">(55)</ref><ref type="bibr" target="#b55">(56)</ref><ref type="bibr" target="#b56">(57)</ref><ref type="bibr" target="#b57">(58)</ref><ref type="bibr" target="#b58">(59)</ref><ref type="bibr" target="#b59">(60)</ref><ref type="bibr" target="#b60">(61)</ref><ref type="bibr" target="#b61">(62)</ref><ref type="bibr" target="#b62">(63)</ref><ref type="bibr" target="#b63">(64)</ref>.</s><s xml:id="_myQQZdu">Some studies appear in more than one category because they evaluated multiple interventions that were applied to different categories.</s><s xml:id="_mSsY744">All studies were evaluated at 10 years or longer.</s><s xml:id="_rwwTSE2">More than half of these studies (or study arms) assessed the CE of two fiscal policiesdSSB taxation and fruit and vegetable subsidies.</s><s xml:id="_2BzJAAb">Among the nine studies (or study arms) that evaluated the CE of SSB taxation, the most common taxation rate was 20% of the total amount paid.</s><s xml:id="_GeExDmy">All nine studies used computer-simulation models and used effectiveness outcomes from published articles.</s><s xml:id="_VtG6E2Q">Two studies used a governmental perspective while the other seven used a health care perspective.</s><s xml:id="_rES9rfw">All nine studies found the SSB tax to be CS.</s><s xml:id="_V44epAu">The included studies also evaluated a sugar tax, a fruit and vegetable subsidy, and a combination of taxing unhealthy foods and subsidizing healthy foods and found large variations in CE outcomes.</s><s xml:id="_D2qgpkR">For nonfiscal policy interventions, such as a walking group in the community, opening supermarkets to increase food access, and increasing healthy food options in the workplace, most of the interventions were cost-effective or CS from the health care system perspective.</s><s xml:id="_XVm2GVD">However, the CE results were inconsistent from the societal perspective.</s><s xml:id="_cHsPTh7">In addition, many of these interventions were only evaluated by one study, such that we were unable to make a definite conclusion on the CE of these interventions.</s></p><p xml:id="_FZnDpnT"><s xml:id="_n5u2R9Q">Table <ref type="table" target="#tab_12">3</ref> summarizes the CE of populationbased approaches.</s><s xml:id="_SB4zZYX">The SSB tax was found to be CS from the health care system and governmental perspectives.</s><s xml:id="_5Vgdvhc">The four studies (or study arms) that evaluated the CE of subsidies for fruits and vegetables found mixed results, from more costly with no net health outcomes benefits to CS.</s><s xml:id="_MaAGWgs">Similarly, the five studies that evaluated community-wide interventions also found them to have various CE outcomes from the health care system and societal perspective.</s><s xml:id="_7EkYHWb">Interventions of incentive programs and environmental change were cost-effective from the health care system perspective.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MqcGXBe">CONCLUSIONS</head><p xml:id="_FWVM4Nv"><s xml:id="_APESr9n">Our systematic review assessed the CE of approaches for preventing T2D from 39 studies.</s><s xml:id="_aDYYtDB">Three key findings emerged.</s><s xml:id="_G5F7gnX">First, the ICERs of most of the high-risk approaches were well below the range that is generally considered to be costeffective.</s><s xml:id="_Fhz5pEZ">Importantly, differences between delivery methods were small, and the group-delivered translational DPP provided by a combination of health professionals and trained lay health workers seemed most cost-effective.</s><s xml:id="_G48g85s">Our findings reinforced the fact that interventions to prevent T2D among highrisk individuals are highly cost-effective and practical in any given setting.</s><s xml:id="_RmACvGs">Second, implementing a population-wide SSB tax was CS and has the potential to benefit a large population.</s><s xml:id="_zeXcdFS">SSB taxation can be considered as an important population-based policy approach to prevent T2D globally.</s><s xml:id="_tkZanQH">Third, although there were many proposed populationbased interventions (including subsidies for fruits and vegetables, health promotion approaches, and environmental changes), the CE of these interventions needs further investigation with real-world data in order to draw a conclusion.</s></p><p xml:id="_7HqmRRv"><s xml:id="_9aGGMNa">Our findings for high-risk approaches are consistent with previous literature in that lifestyle programs utilizing the translational DPP curriculum are somewhat more cost-effective than lifestyle interventions that do not follow the DPP curriculum <ref type="bibr" target="#b16">(17)</ref>.</s><s xml:id="_KBzHPRY">The translational DPP lifestyle program is widely used in the Centers for Disease Control and Prevention (CDC)-led National Diabetes Prevention Program (National DPP)da U.S. translational program providing a framework and infrastructure for targeting high-risk individuals, and this program is covered by several commercial and public insurers <ref type="bibr" target="#b64">(65)</ref>.</s><s xml:id="_k3rKqej">For example, the Centers for Medicare &amp; Medicaid Services began covering the CDC-recognized DPP lifestyle change programs in 2018 for Medicare beneficiaries <ref type="bibr" target="#b65">(66)</ref>.</s></p><p xml:id="_PPSVEJC"><s xml:id="_gfKWST7">A noteworthy change in the high-risk approach category is the adoption of virtual media for intervention delivery.</s><s xml:id="_3RyVcXG">In recent years, virtual media interventions have become available via online counseling calls, emails, and text messages <ref type="bibr" target="#b28">(29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b48">49)</ref>.</s><s xml:id="_wQyKJmY">One benefit of virtual media is that it reaches individuals who have barriers to in-person interventions, such as the elderly and people who live in rural areas.</s><s xml:id="_ekgbVuS">People may take advantage of virtual media interventions to save time and travel expenses <ref type="bibr" target="#b66">(67)</ref>.</s><s xml:id="_UutHZ8R">Virtual media interventions also allow participants to access the program any time and with a greater frequency <ref type="bibr" target="#b67">(68)</ref>.</s><s xml:id="_M98fJsp">Our review found that few studies evaluated the CE of interventions delivered virtually.</s><s xml:id="_hxkmJYR">The results from this limited evidence show that virtually delivered programs were cost-effective but not as cost-effective as the in-person lifestyle program as measured by cost per QALY.</s><s xml:id="_XUYhSFc">Additionally, more rigorous studies are needed to assess the CE of virtually delivered programs.</s><s xml:id="_JRXGQm7">The results of our review also demonstrate great potential for populationbased interventions to prevent T2D (69).</s><s xml:id="_xk6bHYm">Among fiscal policies, taxing SSBs may be a better approach than subsidies for healthy foods for two main reasons: 1) tax policies generated better CE outcomes and 2) evidence supporting tax policies was stronger as multiple studies collectively reached a consistent conclusion.</s><s xml:id="_BbYDv9N">From a health care system perspective, SSB taxes would be CS.</s><s xml:id="_DNFbWET">The SSB tax would reduce SSB consumption at zero or little health intervention costs and would also reduce health care spending.</s><s xml:id="_uZ87sHX">The nine studies in our review showed how much health care costs would be saved from SSB taxation.</s><s xml:id="_csEpyTK">In addition, these studies showed that such an intervention would be CS or cost-effective from the governmental perspective.</s><s xml:id="_ePmT3VV">On the other hand, the ICERs of interventions to promote the consumption of fruits and vegetables ranged widely.</s><s xml:id="_TDy46Sm">These studies differed in features that would change the results, such as the targeted population (general population vs. participants in the Supplemental Nutrition Assistance Program [SNAP]), analytical time horizon (10 years vs. lifetime), and study perspective (governmental, health care system, or societal).</s><s xml:id="_PCMgSzD">Although evidence indicates that an SSB tax could be a CS intervention to prevent T2D, there are political and other considerations that impact its implementation in the real world <ref type="bibr" target="#b69">(70)</ref>.</s><s xml:id="_uRvRyJU">The uptake of that strategy is dependent on state and local decisionmaking <ref type="bibr" target="#b69">(70)</ref><ref type="bibr" target="#b70">(71)</ref><ref type="bibr" target="#b71">(72)</ref>.</s></p><p xml:id="_xVQPkxJ"><s xml:id="_kcXDF3s">Our study is one of the first to include articles evaluating the CE of populationbased approaches to prevent T2D in a systematic review.</s><s xml:id="_NjuMc6S">The adoption of population-based approaches could have great potential for improving population health.</s><s xml:id="_VVNG66X">A recent analysis found that only 3.1% of U.S. adults without T2D (regardless of prediabetes status) met T2D risk reduction lifestyle goals in 2007-2012 <ref type="bibr" target="#b72">(73)</ref>, suggesting the need for broader public health efforts to reach the majority of the U.S. population for reducing their risk of T2D.</s><s xml:id="_uK2QnaM">Individuals at high risk for T2D could benefit from population-based prevention efforts in conjunction with targeted, high-risk approaches.</s><s xml:id="_JgEKqCX">For those who have not been screened for T2D, population-based interventions may also slow their progression to T2D and provide other health benefits from better nutrition and more physical activity <ref type="bibr" target="#b8">(9)</ref>.</s></p><p xml:id="_xTqyT8A"><s xml:id="_x7N4462">Our findings on the CE of both high-risk approaches and population-based approaches indicate that investing in T2D prevention is an efficient use of limited health care and societal resources.</s><s xml:id="_T6gwNG4">Since the development of T2D is a result of a combination of multiple risk factors including genetics, environment, and behaviors, a combined strategy of both highrisk and population-based approaches may be the best one to achieve optimal outcomes of T2D prevention <ref type="bibr" target="#b8">(9,</ref><ref type="bibr" target="#b9">10)</ref>.</s><s xml:id="_nh8Ux6V">Interventions targeting high-risk individuals are effective and cost-effective among individuals at risk for T2D.</s><s xml:id="_hkv25Sk">However, the low uptake and resource-intensive nature of high-risk approaches limit their application.</s><s xml:id="_ZgnNbDB">In contrast, while population-based approaches use "upstream" approaches that reach a broader population, their impact at the individual level is weaker, and the evidence of their effectiveness is more limited.</s></p><p xml:id="_XBU39c3"><s xml:id="_Aaq3duD">Based on our review, we suggest two avenues for the future economic evaluation of T2D prevention approaches.</s><s xml:id="_PvKekb9">The first is to conduct rigorous CEAs using real-world data on populationbased interventions.</s><s xml:id="_tWePY9U">The studies in this review generated considerable variation in CE, indicating uncertainty about the CE of these interventions.</s><s xml:id="_RBkEYYt">Many studies are based on simulation modeling.</s><s xml:id="_CvWEyGm">Although high-quality simulation models can generate reliable results, they rely on strong assumptions that may or may not be reflected in reality.</s><s xml:id="_UE2cKtC">In contrast, data from empirical studiesd natural experiments, for exampledare directly observed and reflect the "true" behavioral change of the population to interventions.</s><s xml:id="_N5N88Z8">Although such studies usually last for a couple of years, they are often the foundation for modeling studies.</s><s xml:id="_JEGrxmS">Additional research that evaluates the impact of taxes, subsidies, food labeling, and other approaches that are already implemented ("natural experiments") are needed to obtain stronger data.</s><s xml:id="_tqM2FhP">Second, effective and cost-effective populationbased approaches are needed for both developing and developed countries.</s><s xml:id="_u7E8Ezj">*Studies included in this table satisfy three conditions: 1) the main objective of a study was evaluating the CE of an intervention, 2) the effect of the intervention was compared with the effect of a "status quo" or a placebo scenario, and 3) the evaluation was from a health care system perspective.</s><s xml:id="_BpYkzt6">â The range of ICER is reported if there are three or more data points.</s><s xml:id="_qA7dJ3k">Costs are in 2017 U.S. dollars.</s><s xml:id="_Percmh5">â¡Translational DPPs refer to diet and physical activity interventions that follow the DPP curriculum that translated to real-world settings, such as provided in the community or primary care.</s><s xml:id="_sCZwy27">In contrast, translational non-DPPs are lifestyle interventions that do not strictly follow the DPP curriculum.</s></p><p xml:id="_kY6myvB"><s xml:id="_qMSd3Wm">Although we found a disproportionate imbalance in the number of studies published involving high-income countries, population-based approaches are strategies to reach a large scale of the population to address the dramatic increase in diabetes prevalence worldwide.</s><s xml:id="_AEuavuN">Conclusions from this review need to be interpreted with caution.</s><s xml:id="_aRXjcsD">First, most of the evaluations, especially populationbased approaches, utilized simulation modeling, which can be heavily influenced by assumptions.</s><s xml:id="_W6B7wZb">Unlike data from clinical trials, which are directly observed, model data are usually from published articles.</s><s xml:id="_m66taCX">Even though many models used data from clinical trials for the initial years of interventions, they must make assumptions on the persistence of costs and effectiveness beyond the trial study period to simulate a longer time horizon.</s><s xml:id="_6H3bNKR">Because of these contraints, in our review, we tried to rely on evidence if it was consistent across multiple modeling studies.</s><s xml:id="_7fdMWMj">Second, in order to include as many studies on population-based interventions as possible, we used somewhat "looser" quality criteria for these studies.</s><s xml:id="_ZfZferN">Many of the population-based approaches did not conduct formal CEA.</s><s xml:id="_Qpggcce">As a result, the CS results from these studies needs to be better understood, as they were a simple comparison of costs given a certain level of health benefit.</s><s xml:id="_yhJWnWT">Also, many of the CE results were estimated from governmental or health care system perspectives rather than a societal perspective.</s><s xml:id="_ScznVyM">Third, the societal perspective defined in population-based approaches was not as inclusive as it was for highrisk approaches.</s><s xml:id="_N8TK5xm">Some cost categories were not included in the societal perspective, such as productivity loss or time cost.</s><s xml:id="_n65mzAN">Fourth, we compared the CE of interventions based on the median ICERs without explicitly considering other study information, such as the evaluation method and rigorousness of data.</s><s xml:id="_295uQ5Y">This comparison follows previous literature <ref type="bibr" target="#b16">(17)</ref> but may not reflect a real difference in CE.</s><s xml:id="_AGyAt3J">Fifth, our results provide information for decision makers to choose among interventions based on CE criteria only.</s><s xml:id="_WNegJvQ">Many other issues such as health equality, acceptability, and feasibility should also be considered in real-world decisionmaking.</s></p><p xml:id="_RK5S2jj"><s xml:id="_5gAxxv7">Evidence from our review indicates that investing in T2D prevention, using either high-risk approaches or populationbased approaches, is an efficient use of health care and societal resources.</s><s xml:id="_fVzfgt7">Given the enormous cost associated with T2D, if health care resources are limited, then prevention is a highly efficient use of such resources.</s><s xml:id="_ctYGe7M">Interventions targeting high-risk individuals with group-delivered translational DPP lifestyle intervention, provided by a combination of health professionals and trained lay health workers, was more cost-effective compared with one-on-one interventions provided by health professionals solely; however, all interventions targeting high-risk individuals were cost-effective.</s><s xml:id="_HkbG8UH">Among population-based approaches, the SSB taxation saves costs and resources of the health care system and government.</s><s xml:id="_rdMh59y">Therefore, expansion of insurance-covered, professional, and lay-delivered group DPPs with a simultaneous institution of SSB taxation can be considered as a priority to stem the rising tide of T2D.</s><s xml:id="_eTfYcDq">A combined approach that targets both high-risk individuals and the whole population could be a policy choice for preventing T2D in the U.S. and probably in other high-income countries.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 -</head><label>1</label><figDesc><div><p xml:id="_gcCCKuQ"><s xml:id="_GweBqsb">Figure 1-Summary of evidence search and selection for T2D prevention approaches.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><figDesc><div><p xml:id="_SN3ASUP"><s xml:id="_YggYPqk">targeting the whole population (population-based approaches)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 -</head><label>1</label><figDesc><div><p><s xml:id="_GYXgVe6">Description of the CE studies for high-risk and population-based T2D prevention approachesA: Interventions targeting high-risk individuals (high-risk approaches)</s></p></div></figDesc><table><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell></cell><cell>$56,484/DALY</cell><cell>averted</cell><cell></cell><cell></cell><cell></cell><cell>$16,269</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>$18,304</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CS from a health care</cell><cell>perspective, cost-</cell><cell>neutral from</cell><cell>a societal</cell><cell>perspective</cell><cell></cell><cell>$998</cell><cell></cell><cell></cell><cell>$578</cell><cell>Continued on p. 1598</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell>and societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell>Health care</cell></row><row><cell>Discount</cell><cell>rate: cost/ Effectiveness</cell><cell>benefit outcomes</cell><cell></cell><cell>3%/0 Reduced T2D</cell><cell>incidence by</cell><cell>15%</cell><cell></cell><cell></cell><cell>3.5%/3.5% Increased 0.17</cell><cell>years spent</cell><cell>diabetes-free</cell><cell>per person</cell><cell></cell><cell></cell><cell></cell><cell>3.5%/3.5% Increased 0.11</cell><cell>years spent</cell><cell>diabetes-free</cell><cell>per person</cell><cell></cell><cell></cell><cell></cell><cell>NR NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>5%/0 Lived 0.8 years</cell><cell>longer after</cell><cell>diagnosis</cell><cell>5%/0 NR</cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell>Simulation</cell><cell>model</cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell>In-person</cell></row><row><cell></cell><cell></cell><cell>Comparison</cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell>No intervention</cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>time horizon</cell><cell></cell><cell>10 years/10</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell>1 year/50</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1 year/50</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3 years/3</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3 years/</cell><cell>lifetime</cell><cell></cell><cell>3 years/</cell><cell>lifetime</cell></row><row><cell></cell><cell></cell><cell>Target population</cell><cell></cell><cell>Individuals aged 55-74</cell><cell>years and individuals</cell><cell>aged 45-54 years</cell><cell>with the risk of T2D</cell><cell></cell><cell>Individuals at risk for</cell><cell>T2D (at least one:</cell><cell>family history of</cell><cell>diabetes,</cell><cell>hypertension,</cell><cell>dyslipidemia, CVD,</cell><cell>or BMI .25)</cell><cell>Individuals at risk for</cell><cell>T2D (at least one:</cell><cell>family history of</cell><cell>diabetes,</cell><cell>hypertension,</cell><cell>dyslipidemia, CVD,</cell><cell>or BMI .25)</cell><cell>Individuals without</cell><cell>diabetes: average</cell><cell>age 48 years,</cell><cell>average BMI 30</cell><cell></cell><cell></cell><cell>Individuals aged 35-75</cell><cell>years</cell><cell></cell><cell>Individuals aged 35-75</cell><cell>years</cell></row><row><cell></cell><cell></cell><cell>Study Intervention</cell><cell>Whether to screen for prediabetes</cell><cell>Colagiuri and Screening for</cell><cell>Walker, prediabetes and</cell><cell>2008/ provide lifestyle</cell><cell>Australia (27) intervention for</cell><cell>those with IGT or IFG</cell><cell>Gillies et al., Screening for IGT and</cell><cell>2008/U.K. provide lifestyle</cell><cell>(28) intervention for</cell><cell>those screened</cell><cell>positive</cell><cell></cell><cell></cell><cell>Gillies et al., Screening for IGT and</cell><cell>2008/U.K. provide metformin</cell><cell>(28) for those screened</cell><cell>positive</cell><cell></cell><cell></cell><cell></cell><cell>Chatterjee et al., Screening for</cell><cell>2010/U.S. prediabetes, provide</cell><cell>(26) lifestyle intervention</cell><cell>using DPP curriculum</cell><cell>for those with IGT or</cell><cell>IFG</cell><cell>Schaufler and Screening for</cell><cell>Wolff, 2010/ prediabetes, provide</cell><cell>Germany (31) lifestyle intervention</cell><cell>using DPP curriculum</cell><cell>for those with IGT or</cell><cell>IFG</cell><cell>Schaufler and Screening for</cell><cell>Wolff, 2010/ prediabetes, provide</cell><cell>Germany (31) metformin for those</cell><cell>with IGT or IFG</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_fQ6mwb7"><s xml:id="_758SvwM">Continued</s></p></div></figDesc><table><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell>Men aged 30 years:</cell><cell>CS; women aged</cell><cell>30: CS; Men aged</cell><cell>50: CS; women</cell><cell>aged 50: CS; Men</cell><cell>aged 70: $51,140;</cell><cell>women aged 70:</cell><cell>$36,078</cell><cell>Initiation age of</cell><cell>25 years: $2,767;</cell><cell>age of 40: $2,073;</cell><cell>age of 60: $4,877</cell><cell>Initiation age of</cell><cell>25 years: $2,793;</cell><cell>age of 40: $2,085;</cell><cell>age of 60: $5,027</cell><cell>Initiation age of</cell><cell>25 years: $2,790;</cell><cell>age of 40: $1,603;</cell><cell>age of 60: $5,010</cell><cell>Initiation age of</cell><cell>25 years: $637;</cell><cell>age of 40: $448;</cell><cell>age of 60: $1,616</cell><cell>Continued on p. 1599</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Effectiveness</cell><cell>outcomes</cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Deferred T2D by</cell><cell>0.49-2.51</cell><cell>years</cell><cell></cell><cell>Deferred T2D by</cell><cell>0.57-2.94</cell><cell>years</cell><cell></cell><cell>Deferred T2D by</cell><cell>0.55-2.88</cell><cell>years</cell><cell></cell><cell>Deferred T2D</cell><cell>by ,0.04 years</cell><cell></cell><cell></cell></row><row><cell>Discount</cell><cell>rate: cost/</cell><cell>benefit</cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell>In-person</cell><cell>and virtual</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell>and virtual</cell><cell></cell><cell></cell><cell>In-person</cell><cell>and virtual</cell><cell></cell><cell></cell><cell>In-person</cell><cell>and virtual</cell><cell></cell><cell></cell><cell>In-person</cell><cell>and virtual</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Comparison</cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>time horizon</cell><cell>5 years/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>6 years/40</cell><cell>years</cell><cell></cell><cell></cell><cell>6 years/40</cell><cell>years</cell><cell></cell><cell></cell><cell>6 years/40</cell><cell>years</cell><cell></cell><cell></cell><cell>6 years/40</cell><cell>years</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Target population</cell><cell>High-risk individuals</cell><cell>identified with</cell><cell>a screening tool such</cell><cell>as the FINDRISC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Individuals aged 25-74</cell><cell>years</cell><cell></cell><cell></cell><cell>Individuals aged 25-74</cell><cell>years</cell><cell></cell><cell></cell><cell>Individuals aged 25-74</cell><cell>years</cell><cell></cell><cell></cell><cell>Individuals aged 25-74</cell><cell>years</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Intervention</cell><cell>Screening for high-risk</cell><cell>people with a self-</cell><cell>administered</cell><cell>questionnaire and</cell><cell>provide lifestyle</cell><cell>intervention</cell><cell></cell><cell></cell><cell>Screening IGT, provide</cell><cell>diet intervention</cell><cell></cell><cell></cell><cell>Screening IGT, provide</cell><cell>physical activity</cell><cell>intervention</cell><cell></cell><cell>Screening IGT, provide</cell><cell>diet and physical</cell><cell>activity intervention</cell><cell></cell><cell>Only screening for IGT</cell><cell>and no follow-up</cell><cell>intervention</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Study</cell><cell>Neumann et al.,</cell><cell>2011/</cell><cell>Germany (30)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Liu et al., 2013/</cell><cell>China (29)</cell><cell></cell><cell></cell><cell>Liu et al., 2013/</cell><cell>China (29)</cell><cell></cell><cell></cell><cell>Liu et al., 2013/</cell><cell>China (29)</cell><cell></cell><cell></cell><cell>Liu et al., 2013/</cell><cell>China (29)</cell><cell></cell><cell></cell></row></table><note xml:id="_2vXVBEz"><p><s xml:id="_HYKd87s">A: Interventions targeting high-risk individuals (high-risk approaches)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_8dRg2MC"><s xml:id="_rqnJmxe">Continued</s></p></div></figDesc><table><row><cell cols="4">care.diabetesjournals.org</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="9">Zhou and Associates 1599</cell></row><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell></cell><cell>If prediabetes</cell><cell>receive DPP</cell><cell>intervention, and</cell><cell>if cutoff was 6.0%</cell><cell>compared with</cell><cell>6.1%, $26,576; if</cell><cell>cutoff was 5.7%</cell><cell>compared with</cell><cell>5.8%, $56,948; if</cell><cell>cutoff was 5.5%</cell><cell>compared with</cell><cell>5.6%, $121,490. If</cell><cell>prediabetes</cell><cell>receive Plan4ward</cell><cell>intervention, and</cell><cell>if cutoff was 6.0%</cell><cell>compared with</cell><cell>6.1%, $22,779; if</cell><cell>cutoff was 5.7%</cell><cell>compared with</cell><cell>5.8%, $43,027; if</cell><cell>cutoff was 5.5%</cell><cell>compared with</cell><cell>5.6%, $88,587</cell><cell>Cutoff of 115 mg/dL</cell><cell>compared with</cell><cell>120 mg/dL,</cell><cell>$34,483; 110 mg/dL</cell><cell>compared with</cell><cell>115 mg/dL,</cell><cell>$37,691; 105 mg/dL</cell><cell>compared with</cell><cell>110 mg/dL,</cell><cell>$48,460; 100 mg/dL</cell><cell>compared with</cell><cell>105 mg/dL,</cell><cell>$69,539; 95 mg/dL</cell><cell>compared with</cell><cell>100 mg/dL,</cell><cell>$93,712; 90 mg/dL</cell><cell>compared with</cell><cell>95 mg/dL, $132,663</cell><cell>Continued on p. 1600</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Effectiveness</cell><cell>outcomes</cell><cell></cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Discount</cell><cell>rate: cost/</cell><cell>benefit</cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Comparison</cell><cell></cell><cell>Same intervention</cell><cell>but prediabetes is</cell><cell>identified by</cell><cell>a different cutoff</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>High-risk people</cell><cell>identified with</cell><cell>a higher threshold</cell><cell>of FPG are</cell><cell>assumed to receive</cell><cell>lifestyle</cell><cell>intervention as in</cell><cell>DPP</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>Study Intervention Target population time horizon</cell><cell>Determining the target population for screening and intervention</cell><cell>Zhuo et al., Screening for Individuals aged 3 years/</cell><cell>2012/U.S. prediabetes with 18 years and older lifetime</cell><cell>(33) different HbA 1c</cell><cell>cutoffs ranging from</cell><cell>6.4% to 5.5%, and</cell><cell>give either lifestyle</cell><cell>intervention as in</cell><cell>DPP or lifestyle</cell><cell>intervention as in</cell><cell>Plan4Ward</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Zhuo et al., High-risk people Individuals aged $45 Until onset of</cell><cell>2013/U.S. identified with years without diabetes/</cell><cell>(34) certain cutoff of FPG diabetes lifetime</cell><cell>are assumed to</cell><cell>receive lifestyle</cell><cell>intervention as in</cell><cell>DPP</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_abpJcyr"><p><s xml:id="_Fw8AbKc">A: Interventions targeting high-risk individuals (high-risk approaches)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_ANRRy5X"><s xml:id="_qMVa4gW">Continued</s></p></div></figDesc><table><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell>Intervention with</cell><cell>low intensity,</cell><cell>$3,680; medium</cell><cell>intensity, $6,544;</cell><cell>high intensity,</cell><cell>$6,192</cell><cell>Intervention with</cell><cell>low intensity,</cell><cell>$7,869; medium</cell><cell>intensity, $9,704;</cell><cell>high intensity,</cell><cell>$9,365</cell><cell>Intervention with</cell><cell>low intensity, CS;</cell><cell>medium intensity,</cell><cell>CS; high intensity,</cell><cell>CS</cell><cell>Intervention with</cell><cell>low intensity, CS;</cell><cell>medium intensity,</cell><cell>CS; high intensity,</cell><cell>CS</cell><cell>Intervention with</cell><cell>low intensity, CS;</cell><cell>medium intensity,</cell><cell>CS; high intensity,</cell><cell>$539</cell><cell>Intervention with</cell><cell>low intensity,</cell><cell>$14,680; medium</cell><cell>intensity, $13,630;</cell><cell>high intensity,</cell><cell>$13,954</cell><cell>$6,235</cell><cell>Continued on p. 1601</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell></row><row><cell>Discount</cell><cell>rate: cost/ Effectiveness</cell><cell>benefit outcomes</cell><cell>1.5%/1.5% Reduced T2D by</cell><cell>19-38 per</cell><cell>1 million</cell><cell>individuals</cell><cell></cell><cell></cell><cell>1.5%/1.5% Reduced T2D by</cell><cell>17-51 per</cell><cell>1 million</cell><cell>individuals</cell><cell></cell><cell></cell><cell>1.5%/1.5% Reduced T2D by</cell><cell>83-235 per</cell><cell>1 million</cell><cell>individuals</cell><cell></cell><cell>1.5%/1.5% Reduced T2D by</cell><cell>63-176 per</cell><cell>1 million</cell><cell>individuals</cell><cell></cell><cell>1.5%/1.5% Reduced T2D by</cell><cell>20-71 per</cell><cell>1 million</cell><cell>individuals</cell><cell></cell><cell>1.5%/1.5% Reduced T2D by</cell><cell>1-4 per</cell><cell>1 million</cell><cell>individuals</cell><cell></cell><cell></cell><cell>3%/3% Reduce diabetes</cell><cell>incidence by</cell><cell>19.8%</cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell></row><row><cell></cell><cell></cell><cell>Comparison</cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>time horizon</cell><cell>1 year/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1 year/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1 year/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell>1 year/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell>1 year/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell>1 year/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>12-14 weeks/</cell><cell>3 years</cell></row><row><cell></cell><cell></cell><cell>Study Intervention Target population</cell><cell>Breeze et al., Lifestyle intervention Individuals aged 40-65</cell><cell>2017/U.K. among adults aged years</cell><cell>(32) 40-65 years, data</cell><cell>from literature</cell><cell></cell><cell></cell><cell>Breeze et al., Lifestyle intervention Individuals in the</cell><cell>2017/U.K. among low lowest quantile of</cell><cell>(32) socioeconomic deprivation</cell><cell>status people, data</cell><cell>from literature</cell><cell></cell><cell>Breeze et al., Lifestyle intervention Individuals with</cell><cell>2017/U.K. among people HbA 1c .42 mmol/</cell><cell>(32) HbA 1c .42 mmol/ mol (6%)</cell><cell>mol (6%), data from</cell><cell>literature</cell><cell>Breeze et al., Lifestyle intervention Individuals with</cell><cell>2017/U.K. among people with FINDRISC probability</cell><cell>(32) FINDRISC probability score .0.1</cell><cell>score .0.1, data</cell><cell>from literature</cell><cell>Breeze et al. Lifestyle intervention Individuals with</cell><cell>2017/U.K. among people with a BMI .35</cell><cell>(32) BMI .35, data from</cell><cell>literature</cell><cell></cell><cell>Breeze et al. Lifestyle intervention South Asians</cell><cell>2017/U.K. among South Asians,</cell><cell>(32) data from literature</cell><cell></cell><cell></cell><cell>Evaluating the CE of T2D prevention approaches</cell><cell>Smith et al. Modified DPP Individuals with</cell><cell>2010/U.S. intervention BMI $25 and</cell><cell>(46) adapted to the metabolic syndrome</cell><cell>group-based setting</cell></row></table><note xml:id="_mdt95CS"><p><s xml:id="_3Qrdcxe">A: Interventions targeting high-risk individuals (high-risk approaches)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_Zvtmsuy"><s xml:id="_HfBHerD">Continued</s></p></div></figDesc><table><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell>Health care</cell><cell>perspective,</cell><cell>$15,759; societal</cell><cell>perspective,</cell><cell>$24,244</cell><cell></cell><cell>CS from both</cell><cell>perspectives</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell>perspective,</cell><cell>$18,216; societal</cell><cell>perspective,</cell><cell>$56,129</cell><cell></cell><cell>$10,174</cell><cell></cell><cell></cell><cell></cell><cell>CS</cell><cell></cell><cell></cell><cell></cell><cell>CS</cell><cell>Continued on p. 1602</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell>Health care</cell><cell>and societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell>and societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell>and societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell></row><row><cell></cell><cell>Effectiveness</cell><cell>outcomes</cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Reduce diabetes</cell><cell>incidence by</cell><cell>6.6%</cell><cell></cell><cell>Reduce diabetes</cell><cell>incidence by</cell><cell>18.2%</cell><cell></cell><cell>Prevent or delay</cell><cell>diabetes</cell><cell>among</cell><cell>intervention</cell><cell>group by 7%</cell></row><row><cell>Discount</cell><cell>rate: cost/</cell><cell>benefit</cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>5%/5%</cell><cell></cell><cell></cell><cell></cell><cell>5%/5%</cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell></row><row><cell></cell><cell></cell><cell>Comparison</cell><cell>Placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Metformin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>time horizon</cell><cell>10 years/10</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10 years/10</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10 years/10</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10 years/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell>10 years/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell>Until the</cell><cell>onset of</cell><cell>diabetes/</cell><cell>25 years</cell></row><row><cell></cell><cell></cell><cell>Target population</cell><cell>Individuals aged $25</cell><cell>years with IGT and</cell><cell>fasting</cell><cell>hyperglycemia,</cell><cell>BMI $24 (BMI $22</cell><cell>in Asian Americans)</cell><cell>Individuals aged $25</cell><cell>years with IGT and</cell><cell>fasting</cell><cell>hyperglycemia,</cell><cell>BMI $24 (BMI $22</cell><cell>in Asian Americans)</cell><cell>Individuals aged $25</cell><cell>years with IGT and</cell><cell>fasting</cell><cell>hyperglycemia,</cell><cell>BMI $24 (BMI $22</cell><cell>in Asian Americans)</cell><cell>Individuals mean age</cell><cell>50.6 years, 67.8%</cell><cell>female, mean BMI</cell><cell>34, and IGT present</cell><cell>Individuals mean age</cell><cell>50.6 years, 67.8%</cell><cell>female, mean BMI</cell><cell>34, and IGT present</cell><cell>Individuals aged 18-84</cell><cell>years with</cell><cell>prediabetes</cell></row><row><cell></cell><cell></cell><cell>Intervention</cell><cell>DPP/DPPOS: lifestyle</cell><cell>for 16-session core</cell><cell>curriculum and</cell><cell>subsequent</cell><cell>individual and group</cell><cell>sessions</cell><cell>Metformin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>DPP/DPPOS: lifestyle</cell><cell>for 16-session core</cell><cell>curriculum and</cell><cell>subsequent</cell><cell>individual and group</cell><cell>sessions</cell><cell>Metformin</cell><cell></cell><cell></cell><cell></cell><cell>Intensive lifestyle</cell><cell>changes as in DPP</cell><cell></cell><cell></cell><cell>DPP lifestyle</cell><cell>intervention</cell><cell>adapted to</cell><cell>a community setting</cell></row><row><cell></cell><cell></cell><cell>Study</cell><cell>DPP Research</cell><cell>Group, 2012/</cell><cell>U.S. (35)</cell><cell></cell><cell></cell><cell></cell><cell>DPP Research</cell><cell>Group, 2012/</cell><cell>U.S. (35)</cell><cell></cell><cell></cell><cell></cell><cell>DPP Research</cell><cell>Group, 2012/</cell><cell>U.S. (35)</cell><cell></cell><cell></cell><cell></cell><cell>Palmer and</cell><cell>Tucker, 2012/</cell><cell>Australia (42)</cell><cell></cell><cell>Palmer and</cell><cell>Tucker, 2012/</cell><cell>Australia (42)</cell><cell></cell><cell>Zhuo et al.,</cell><cell>2012/U.S.</cell><cell>(50)</cell></row></table><note xml:id="_rKrwdR8"><p><s xml:id="_mN9pRJ4">A: Interventions targeting high-risk individuals (high-risk approaches)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_RSY9H48"><s xml:id="_ujDhT4x">Continued</s></p></div></figDesc><table><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell>Societal perspective:</cell><cell>$10,719 for men</cell><cell>with low risk and</cell><cell>CS for men with</cell><cell>medium and high</cell><cell>risk; $10,808 for</cell><cell>women with low</cell><cell>risk, $5,315 for</cell><cell>women with</cell><cell>medium risk, and</cell><cell>$26,798 for</cell><cell>women with high</cell><cell>risk. Health care</cell><cell>perspective:</cell><cell>$16,519 for men</cell><cell>with low risk,</cell><cell>$7,443 for men</cell><cell>with medium risk,</cell><cell>and $4,869 for</cell><cell>men with high risk;</cell><cell>$15,756 for</cell><cell>women with low</cell><cell>risk, $10,871 for</cell><cell>women with</cell><cell>medium risk, and</cell><cell>$27,605 for</cell><cell>women with high</cell><cell>risk</cell><cell>$24,460 from</cell><cell>a health care</cell><cell>perspective and</cell><cell>$3,959 from</cell><cell>a societal</cell><cell>perspective</cell><cell>$24,061 from</cell><cell>a health care</cell><cell>perspective and</cell><cell>$31,382 from</cell><cell>a societal</cell><cell>perspective</cell><cell>Continued on p. 1603</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell>Health care</cell><cell>and societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell>and societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell>and societal</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Effectiveness</cell><cell>outcomes</cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Reduced</cell><cell>diabetes</cell><cell>incidence by</cell><cell>49.4%</cell><cell></cell><cell></cell><cell>Reduced</cell><cell>diabetes</cell><cell>incidence by</cell><cell>36%</cell><cell></cell><cell></cell></row><row><cell>Discount</cell><cell>rate: cost/</cell><cell>benefit</cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Comparison</cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Metformin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>time horizon</cell><cell>1 year/</cell><cell>lifetime</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10 years/10</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10 years/10</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Target population</cell><cell>People with diagnosed</cell><cell>metabolic syndrome</cell><cell>(33% have diabetes</cell><cell>already): mean age</cell><cell>53 years, mean BMI</cell><cell>32.5 for men and</cell><cell>32.3 for women</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Individuals aged $25</cell><cell>years, with IGT and</cell><cell>fasting</cell><cell>hyperglycemia,</cell><cell>BMI $24 (Asians</cell><cell>BMI $22)</cell><cell>Individuals aged $25</cell><cell>years, with IGT and</cell><cell>fasting</cell><cell>hyperglycemia,</cell><cell>BMI $24 (Asians</cell><cell>BMI $22)</cell></row><row><cell></cell><cell></cell><cell>Intervention</cell><cell>Primary care-based</cell><cell>lifestyle counseling</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>DPP/DPPOS: lifestyle</cell><cell>for 16-session core</cell><cell>curriculum and</cell><cell>subsequent</cell><cell>individual and group</cell><cell>sessions</cell><cell>DPP/DPPOS: lifestyle</cell><cell>for 16-session core</cell><cell>curriculum and</cell><cell>subsequent</cell><cell>individual and group</cell><cell>sessions</cell></row><row><cell></cell><cell></cell><cell>Study</cell><cell>Feldman et al.,</cell><cell>2013/</cell><cell>Sweden (51)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Herman et al.,</cell><cell>2013/U.S.</cell><cell>(36)</cell><cell></cell><cell></cell><cell></cell><cell>Herman et al.,</cell><cell>2013/U.S.</cell><cell>(36)</cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_XNh2Byn"><p><s xml:id="_TR23BJc">A: Interventions targeting high-risk individuals (high-risk approaches)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_kzrVkyr"><s xml:id="_JXDPvBQ">Continued</s></p></div></figDesc><table><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell>2% weight loss goal:</cell><cell>ICER was $68,203,</cell><cell>$207,369, and</cell><cell>$578,494 for 20,</cell><cell>10, and 5-year</cell><cell>time horizon,</cell><cell>respectively; 5%</cell><cell>weight loss goal:</cell><cell>ICER was $73,504,</cell><cell>$222,603, and</cell><cell>$668,751 for 20,</cell><cell>10, and 5-year</cell><cell>time horizon,</cell><cell>respectively</cell><cell>$10,342</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CS</cell><cell></cell><cell></cell><cell></cell><cell>Male: initiation age</cell><cell>30 years, $7,626;</cell><cell>initiation age 50,</cell><cell>$11,303; initiation</cell><cell>age 70, $17,108</cell><cell>Female: initiation</cell><cell>age 30 years,</cell><cell>$7,116; initiation</cell><cell>age 50, $10,501;</cell><cell>initiation age 70,</cell><cell>$16,204</cell><cell>Continued on p. 1607</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell></row><row><cell></cell><cell>Effectiveness</cell><cell>outcomes</cell><cell>34% sample had</cell><cell>a 2% weight</cell><cell>loss, 14%</cell><cell>sample had</cell><cell>a 5% weight</cell><cell>loss</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Reduce waist</cell><cell>circumference</cell><cell>by 0.68 cm</cell><cell>(10%), reduce</cell><cell>weight by</cell><cell>1.11 kg (18%),</cell><cell>reduce BMI by</cell><cell>0.28 (14%)</cell><cell>Reduced T2D</cell><cell>incidence by</cell><cell>5%</cell><cell></cell><cell>NR</cell></row><row><cell>Discount</cell><cell>rate: cost/</cell><cell>benefit</cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell><cell></cell><cell></cell><cell></cell><cell>3%/3%</cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Virtual</cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>time horizon Comparison</cell><cell>12 weeks/5 No intervention</cell><cell>years,</cell><cell>10 years,</cell><cell>20 years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1 year/1 year Telephone</cell><cell>adaptations of the</cell><cell>DPP lifestyle</cell><cell>intervention, with</cell><cell>individual call</cell><cell></cell><cell></cell><cell></cell><cell>2 years/ No intervention</cell><cell>lifetime</cell><cell></cell><cell></cell><cell>5 years/ No intervention</cell><cell>lifetime</cell></row><row><cell></cell><cell></cell><cell>Target population</cell><cell>Lower socioeconomic</cell><cell>status community</cell><cell>with largely female,</cell><cell>middle-aged, and</cell><cell>Mexico-born; 32%</cell><cell>overweight and</cell><cell>more than half</cell><cell>obese</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Individuals with</cell><cell>diagnosed metabolic</cell><cell>syndrome: largely</cell><cell>female, middle-</cell><cell>aged, and Hispanic</cell><cell></cell><cell></cell><cell></cell><cell>Individuals with</cell><cell>prediabetes</cell><cell></cell><cell></cell><cell>Individuals at risk for</cell><cell>diabetes</cell></row><row><cell></cell><cell></cell><cell>Intervention</cell><cell>Community-based</cell><cell>lifestyle intervention</cell><cell>and weight control</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Telephone adaptations</cell><cell>of the DPP lifestyle</cell><cell>intervention, with</cell><cell>conference calls</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Short text message on</cell><cell>lifestyle intervention</cell><cell></cell><cell></cell><cell>Lifestyle intervention</cell><cell>comparable to the</cell><cell>Finnish Diabetes</cell><cell>Prevention Study</cell></row><row><cell></cell><cell></cell><cell>Study</cell><cell>Wilson et al.,</cell><cell>2015/U.S.</cell><cell>(48)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Hollenbeak</cell><cell>et al., 2016/</cell><cell>U.S. (38)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Wong et al.,</cell><cell>2016/China-</cell><cell>Hong Kong</cell><cell>(49)</cell><cell>Neumann et al.,</cell><cell>2017/</cell><cell>Sweden (41)</cell></row></table><note xml:id="_ZNmHf7P"><p><s xml:id="_6p52Jej">A: Interventions targeting high-risk individuals (high-risk approaches)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 1 -</head><label>1</label><figDesc><div><p xml:id="_x73sNdF"><s xml:id="_vucX6xw">Continued</s></p></div></figDesc><table><row><cell></cell><cell>ICER, $/QALY</cell><cell>(in 2017 US$)</cell><cell>$6,355</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>$15,179</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>More cost, less</cell><cell>effective</cell></row><row><cell></cell><cell></cell><cell>Perspective</cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Societal</cell></row><row><cell>Discount</cell><cell>rate: cost/ Effectiveness</cell><cell>benefit outcomes</cell><cell>3.5%/3.5% NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3%/3% NR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>NR No significant</cell><cell>effect on</cell><cell>maternal</cell><cell>fasting blood</cell><cell>glucose or</cell><cell>birth weight</cell></row><row><cell></cell><cell>Study</cell><cell>method</cell><cell>Trial</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Simulation</cell><cell>model</cell><cell></cell><cell></cell><cell></cell><cell>Trial</cell></row><row><cell></cell><cell>Intervention</cell><cell>media</cell><cell>In-person</cell><cell>and virtual</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>In-person</cell></row><row><cell></cell><cell></cell><cell>Comparison</cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No intervention</cell></row><row><cell>Duration/</cell><cell>analytical</cell><cell>time horizon</cell><cell>3 years/3</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1 year/25</cell><cell>years</cell><cell></cell><cell></cell><cell></cell><cell>During</cell><cell>pregnancy/</cell><cell>lifetime</cell></row><row><cell></cell><cell></cell><cell>Target population</cell><cell>Individuals with</cell><cell>prediabetes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Individuals aged $18</cell><cell>years, overweight or</cell><cell>obese and with at</cell><cell>least one CVD risk</cell><cell>factor including</cell><cell>metabolic syndrome</cell><cell>or elevated blood</cell><cell>pressure, lipids, or</cell><cell>glucose level, but no</cell><cell>history of CVD</cell><cell>Pregnant women with</cell><cell>a risk of developing</cell><cell>GDM</cell></row><row><cell></cell><cell></cell><cell>Intervention</cell><cell>Lifestyle intervention:</cell><cell>receive a booklet,</cell><cell>structured</cell><cell>education, nursing</cell><cell>support phone calls,</cell><cell>group-based</cell><cell>maintenance</cell><cell>sessions</cell><cell>Lifestyle counseling,</cell><cell>data based on the</cell><cell>USPSTF review</cell><cell></cell><cell></cell><cell>Lifestyle intervention,</cell><cell>group-based</cell><cell>exercise program</cell></row><row><cell></cell><cell></cell><cell>Study</cell><cell>Leal et al., 2017/</cell><cell>U.K. (39)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Lin et al., 2017/</cell><cell>U.S. (40)</cell><cell></cell><cell></cell><cell></cell><cell>Managing GDM</cell><cell>Oostdam et al.,</cell><cell>2012/the</cell><cell>Netherlands</cell><cell>(53)</cell><cell>Kolu et al.,</cell><cell>2016/Finland</cell></row></table><note xml:id="_tPvCV3x"><p><s xml:id="_js85pwW">A: Interventions targeting high-risk individuals (high-risk approaches)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>Table 1</head><label>1</label><figDesc><div><p xml:id="_dqwr6vK"><s xml:id="_uptWSp8">CVD, cardiovascular disease; DPPOS, Diabetes Prevention Program Outcomes Study; FINDRISC, Finnish Diabetes Risk Score; FPG, fasting plasma glucose; GDM, gestational diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NR, not reported; N/A, not applicable; Plan4ward, Promoting a Lifestyle of Activity and Nutrition for Working to Alter the Risk of Diabetes; USPSTF, U.S. Preventive Services Task Force.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>ICER, $/QALY</cell><cell>Perspective (in 2017 US$)</cell><cell></cell><cell>Governmental More cost no change</cell><cell>in benefit</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Governmental $1,000,359</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Societal CS</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Health care More cost and less</cell><cell>benefit</cell><cell></cell><cell></cell><cell></cell><cell>Health care CS</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Governmental CS</cell><cell></cell><cell>Continued on p. 1610</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Effectiveness</cell><cell>outcomes</cell><cell></cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yes</cell><cell></cell><cell></cell></row><row><cell>-Continued</cell><cell>B: Interventions targeting the whole population (population-based approaches)</cell><cell>Duration/ Discount</cell><cell>analytical Intervention Study rate: cost/</cell><cell>Study Intervention Target population time horizon Comparison media method benefit</cell><cell>Fiscal policy -fruits and vegetable subsidy</cell><cell>Basu et al., A reward of 30 cents SNAP participants aged 10 years N/A N/A N/A 3%/3%</cell><cell>2013/U.S. added to SNAP 25-64 years</cell><cell>(55) purchase cards for</cell><cell>every $1 of fruits and</cell><cell>vegetables</cell><cell>purchased using</cell><cell>SNAP benefits</cell><cell>Basu et al., A subsidy of 30 cents of SNAP participants aged 10 years N/A N/A N/A 3%/3%</cell><cell>2013/U.S. every $1 of fruits and 25-64 years</cell><cell>(55) vegetables</cell><cell>purchased using</cell><cell>SNAP benefits</cell><cell>Choi et al., A subsidy of 30 cents of SNAP participants aged Lifetime N/A N/A N/A 3%/3%</cell><cell>2017/U.S. every $1 of fruits and 0-85 years</cell><cell>(62) vegetables</cell><cell>purchased using</cell><cell>SNAP benefits</cell><cell>Cobiac et al., A subsidy of $0.15/ Nationwide Lifetime N/A N/A N/A 3%/3%</cell><cell>2017/ 100 g of fruits and</cell><cell>Australia (61) vegetables</cell><cell>purchased</cell><cell>Fiscal policy -combined tax and subsidy</cell><cell>Cobiac et al. A combination of taxes Nationwide Lifetime N/A N/A N/A 3%/3%</cell><cell>2017/ on saturated fat, salt,</cell><cell>Australia (61) SSB, and sugar as well</cell><cell>as subsidies on fruits</cell><cell>and vegetables</cell><cell>Regulation</cell><cell>Basu et al., The ban on using SNAP SNAP participants aged 10 years N/A N/A N/A 3%/3%</cell><cell>2013/U.S. dollars for SSB 25-64 years</cell><cell>(55) purchases</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head>Table 2 -</head><label>2</label><figDesc><div><p xml:id="_tC56kks"><s xml:id="_ATkb5ng">Summary of the CE of interventions targeting high-risk individuals for T2D prevention*</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Median ICER</cell></row><row><cell></cell><cell></cell><cell>(range), $/QALY,</cell></row><row><cell></cell><cell>Study</cell><cell>health care system</cell></row><row><cell>Group</cell><cell>arm, n</cell><cell>perspective â </cell></row><row><cell>Prevention strategy</cell><cell></cell><cell></cell></row><row><cell>Lifestyle</cell><cell>13</cell><cell>$12,510 (CS-$24,368)</cell></row><row><cell>Metformin</cell><cell>4</cell><cell>$17,089 (CS-$24,606)</cell></row><row><cell>Type of lifestyle intervention</cell><cell></cell><cell></cell></row><row><cell>Translational DPP â¡</cell><cell>7</cell><cell>$6,212 (CS-$24,368)</cell></row><row><cell>Translational non-DPP</cell><cell>6</cell><cell>$13,228 (CS-$16,177)</cell></row><row><cell>Time horizon of lifestyle intervention</cell><cell></cell><cell></cell></row><row><cell>,10 years</cell><cell>5</cell><cell>$19,612 ($6,212-$45,358)</cell></row><row><cell>$10 years</cell><cell>10</cell><cell>$13,779 (CS-$24,368)</cell></row><row><cell>Intervention media of lifestyle intervention</cell><cell></cell><cell></cell></row><row><cell>In-person</cell><cell>8</cell><cell>$10,956 (CS-$24,368)</cell></row><row><cell>Virtual</cell><cell>3</cell><cell>$12,510 (CS-$13,944)</cell></row><row><cell>Combination of both</cell><cell>2</cell><cell>$6,331, $15,122</cell></row><row><cell>The delivery setting of in-person lifestyle intervention</cell><cell></cell><cell></cell></row><row><cell>One-on-one</cell><cell>5</cell><cell>$15,700 (CS-$24,368)</cell></row><row><cell>Group</cell><cell>2</cell><cell>CS, $6,212</cell></row><row><cell>Combination of both</cell><cell>1</cell><cell>$16,177</cell></row><row><cell>Provider of in-person lifestyle intervention</cell><cell></cell><cell></cell></row><row><cell>Health professionals</cell><cell>5</cell><cell>$15,700 (CS-$24,368)</cell></row><row><cell>Health professionals and trained lay health workers</cell><cell>3</cell><cell>$6,212 (CS-$16,177)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_12"><head>Table 3 -</head><label>3</label><figDesc><div><p><s xml:id="_RnQugJE">Summary of the CE of population-based T2D prevention approachesof taxing $1.45/100 g of saturated fat, $0.32/1 g of sodium, $0.5/liter of SSB, $0.99/100 mL of ice cream, $0.9/100 g of sugar of all other products, and subsidizing $0.15/ 100 g of fruits and vegetables 1 Health care CS Ban on using SNAP dollars for SSB purchases 1 Governmental CS Community-wide programs for health education (newspaper column, booklet, television news, talks, seminars, workshops, and diet and cooking classes) and physical activity promotion (organized walking events, worksite exercise programs, financial incentives, home visits, and phone calls) The mass media campaign, including television advertising, advertisements in print media, a tollfree telephone line for community-level support, and marketing of campaign merchandise 1 Health care CS Targeted incentive program, including distributing tailored maps of local walking paths and bus schedules, using merchandise as incentive or reward for reducing the use of cars, and encouraging use of pedometers Environmental change, including building bicycle paths, extending hours at recreation facilities, opening fitness centers, increasing the convenient supply of healthy foods, nutrition information pamphlets placed on dining tables, color-coded labeling for foods, opening new supermarkets, and increasing healthy food options in workplace cafeterias For studies that did not conduct formal CEA, CS indicates that the intervention reduces cost.</s></p></div></figDesc><table><row><cell></cell><cell>Study</cell><cell></cell><cell></cell></row><row><cell>Intervention</cell><cell>arm, n</cell><cell>Perspective</cell><cell>CE outcome*</cell></row><row><cell>Penny-per-ounce, 10-20%, or $0.5/liter tax on SSB</cell><cell>9</cell><cell>Health care and</cell><cell>CS</cell></row><row><cell></cell><cell></cell><cell>governmental</cell><cell></cell></row><row><cell>Tax sugar for $0.99/100 mL of ice cream and $0.9/100 g</cell><cell></cell><cell></cell><cell></cell></row><row><cell>of all other products</cell><cell>1</cell><cell>Health care</cell><cell>CS</cell></row><row><cell>30% subsidy for the consumption of fruits and vegetables among SNAP beneficiaries</cell><cell>4</cell><cell>Health care,</cell><cell>CS to worse health</cell></row><row><cell></cell><cell></cell><cell>governmental,</cell><cell>and more cost</cell></row><row><cell></cell><cell></cell><cell>and societal</cell><cell></cell></row><row><cell cols="2">A bundled policy 5</cell><cell>Health care</cell><cell>CS to not</cell></row><row><cell></cell><cell></cell><cell>and societal</cell><cell>cost-effective</cell></row><row><cell></cell><cell>2</cell><cell>Health care</cell><cell>CS to</cell></row><row><cell></cell><cell></cell><cell></cell><cell>cost-effective</cell></row><row><cell>Internet intervention, including giving access to physical activity information and advice through</cell><cell></cell><cell></cell><cell></cell></row><row><cell>website and e-mail</cell><cell>1</cell><cell>Health care</cell><cell>Cost-effective</cell></row><row><cell></cell><cell>3</cell><cell>Health care</cell><cell>CS to</cell></row><row><cell></cell><cell></cell><cell>and societal</cell><cell>cost-effective</cell></row></table><note xml:id="_rKZ4d7y"><p><s xml:id="_pfxVvhr">*</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1594" xml:id="foot_0"><p xml:id="_GyBSr5n"><s xml:id="_egejY8t">Systematic Review of CE Analysis of T2D Prevention Diabetes Care Volume 43, July 2020 Downloaded from http://diabetesjournals.org/care/article-pdf/43/7/1593/630336/dci200018.pdf by guest on 14 August 2025</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_vWrwCU8"><s xml:id="_CxSm64A">Downloaded from http://diabetesjournals.org/care/article-pdf/43/7/1593/630336/dci200018.pdf by guest on 14 August 2025</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div xml:id="_ZThbJab"><p xml:id="_hWjnmmt"><s xml:id="_NHreBBq">Acknowledgments.</s><s xml:id="_hy23KBZ">This work is a collaboration between the <rs type="institution">Centers for Disease Control and Prevention</rs> and the <rs type="funder">American Diabetes Association</rs>.</s><s xml:id="_6xe3vyQ">The authors thank the external and internal reviewers for their valuable comments during the review process.</s><s xml:id="_uMDqqQJ">The authors thank <rs type="person">Rui Li</rs> (<rs type="affiliation">CDC</rs>) for generously sharing materials from her previous review and providing guidance, <rs type="person">William Thomas</rs> (<rs type="affiliation">CDC</rs>) for his timely help with the literature search, and <rs type="person">Clarice G. Conley</rs> (<rs type="affiliation">CDC</rs>) for her editorial assistance.</s><s xml:id="_brqzEHQ">Duality of Interest.</s><s xml:id="_JMtt624">No potential conflicts of interest relevant to this article were reported.</s><s xml:id="_WB2Y4a8">Author Contributions.</s><s xml:id="_skhU2j3">X.Zho.</s><s xml:id="_fh4Nquf">and P.Z.</s><s xml:id="_vQZu3dA">designed the research.</s><s xml:id="_84ZHQkZ">X.Zho.</s><s xml:id="_4bAf3Xw">analyzed data, interpreted results, and drafted the manuscript.</s><s xml:id="_GbMmRWQ">K.R.S. made a critical revision of the manuscript.</s><s xml:id="_gNHz6qM">X.Zho., K.R.S., B.P.N., S.J., and K.K.P. screened studies and abstracted data.</s><s xml:id="_EeQwK54">B.P.N., X.Zha., A.L.A., and P.Z.</s><s xml:id="_EAgV69Q">provided important intellectual content to the manuscript.</s></p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_dwZUb9x" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<idno type="DOI">10.1163/1570-6664_iyb_sim_org_38965</idno>
		<title level="m" xml:id="_S24aXDz">International Diabetes Federation. IDF Diabetes Atlas</title>
		<meeting><address><addrLine>Brussels, Belgium</addrLine></address></meeting>
		<imprint>
			<publisher>International Diabetes Federation</publisher>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note>9th ed.</note>
	<note type="raw_reference">International Diabetes Federation. IDF Dia- betes Atlas, 9th ed. Brussels, Belgium, Interna- tional Diabetes Federation, 2019</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_ghPpNv4">The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Bommer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Heesemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sagalova</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2213-8587(17)30097-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rSfjvKM">Lancet Diabetes Endocrinol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="423" to="430" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 2017;5:423-430</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Atlanta</surname></persName>
		</author>
		<idno type="DOI">10.1037/e494492006-007</idno>
		<imprint>
			<date type="published" when="2020">2020</date>
			<publisher>US Department of Health and Human Services</publisher>
		</imprint>
		<respStmt>
			<orgName>Centers for Disease Control and Prevention</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Atlanta, GA, Centers for Disease Control and Prevention, US Department of Health and Human Services, 2020</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_rs8GpaH">Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetesd2020</title>
		<idno type="DOI">10.2337/dc20-s003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4wRXC97">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="32" to="S36" />
			<date type="published" when="2020">2020</date>
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
	<note>Suppl.</note>
	<note type="raw_reference">American Diabetes Association. 3. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetesd2020. Diabetes Care 2020; 43(Suppl. 1):S32-S36</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_utJQQgA">2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020</title>
		<idno type="DOI">10.2337/dc20-s002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RBNa37S">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="14" to="S31" />
			<date type="published" when="2020">2020</date>
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
	<note>Suppl.</note>
	<note type="raw_reference">American Diabetes Association. 2. Classifica- tion and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(Suppl. 1):S14-S31</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_fBnSfaT">Fiscal policy to improve diets and prevent noncommunicable diseases: from recommendations to action</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Thow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Downs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Trevena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Waqanivalu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cawley</surname></persName>
		</author>
		<idno type="DOI">10.2471/blt.17.195982</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CmSe2mD">Bull World Health Organ</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="201" to="210" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thow AM, Downs SM, Mayes C, Trevena H, Waqanivalu T, Cawley J. Fiscal policy to improve diets and prevent noncommunicable diseases: from recommendations to action. Bull World Health Organ 2018;96:201-210</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_kxRDwAw">Beverages sales in Mexico before and after implementation of a sugar sweetened beverage tax</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Colchero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Guerrero-LÃ³pez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Molina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Rivera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GChJzVX">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">163463</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Colchero MA, Guerrero-LÃ³pez CM, Molina M, Rivera JA. Beverages sales in Mexico before and after implementation of a sugar sweetened bev- erage tax. PLoS One 2016;11:e0163463</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_qWDpWjQ">Impact of the Berkeley excise tax on sugar-sweetened beverage consumption</title>
		<author>
			<persName><forename type="first">J</forename><surname>Falbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rojas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Mcculloch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Madsen</surname></persName>
		</author>
		<idno type="DOI">10.2105/ajph.2016.303362</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TrzERUt">Am J Public Health</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1865" to="1871" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Falbe J, Thompson HR, Becker CM, Rojas N, McCulloch CE, Madsen KA. Impact of the Berke- ley excise tax on sugar-sweetened beverage consumption. Am J Public Health 2016;106: 1865-1871</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_S98s93R">Preventing type 2 diabetes in communities across the U.S.: the National Diabetes Prevention Program</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Albright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2012.12.009</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6vqSZwr">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="346" to="S351" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl.</note>
	<note type="raw_reference">Albright AL, Gregg EW. Preventing type 2 diabetes in communities across the U.S.: the National Diabetes Prevention Program. Am J Prev Med 2013;44(Suppl. 4):S346-S351</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main" xml:id="_g5GGUbG">Population and individual approaches to the prevention and management of diabetes and obesity</title>
		<author>
			<persName><forename type="first">Pan</forename><surname>American</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Health</forename><surname>Organization</surname></persName>
		</author>
		<ptr target="https://www.paho.org/hq/dmdocuments/2012/DMPLAN-ENGLISH.pdf" />
		<imprint>
			<date type="published" when="2011-05-11">2011. Accessed 11 May 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pan American Health Organization. Popula- tion and individual approaches to the prevention and management of diabetes and obesity. 2011. Accessed 11 May 2020. Available from https://www .paho.org/hq/dmdocuments/2012/DMPLAN-ENGLISH .pdf</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_wBETeFF">Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Dunkley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Bodicoat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Greaves</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc14-er06</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pUAMHge">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="922" to="933" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dunkley AJ, Bodicoat DH, Greaves CJ, et al. Diabetes prevention in the real world: effective- ness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care 2014;37:922-933</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_SxThf2u">How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Echouffo-Tcheugui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Williamson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WVMuhfY">Health Aff (Millwood)</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="67" to="75" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ali MK, Echouffo-Tcheugui J, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Aff (Mill- wood) 2012;31:67-75</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_ztYhvAX">A systematic review of real-world diabetes prevention programs: learnings from the last 15 years</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Aziz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Absetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oldroyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Pronk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Oldenburg</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13012-015-0354-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_knBXcwZ">Implement Sci</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">172</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world diabetes prevention programs: learnings from the last 15 years. Implement Sci 2015;10:172</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_TY4rzwZ">Effectiveness of program modification strategies of the diabetes prevention program: a systematic review</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Neamah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sebert</forename><surname>Kuhlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Tabak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XKCBbxv">Diabetes Educ</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="153" to="165" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Neamah HH, Sebert Kuhlmann AK, Tabak RG. Effectiveness of program modification strategies of the diabetes prevention program: a systematic review. Diabetes Educ 2016;42:153-165</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_VhEpyhM">Longterm sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Haw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Galaviz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Straus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_axpK8FK">JAMA Intern Med</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page" from="1808" to="1817" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Haw JS, Galaviz KI, Straus AN, et al. Long- term sustainability of diabetes prevention ap- proaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2017;177:1808-1817</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_DxDyVc3">The effectiveness and cost of lifestyle interventions including nutrition education for diabetes prevention: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Estabrooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Davy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DjCwqZH">J Acad Nutr Diet</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page">36</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sun Y, You W, Almeida F, Estabrooks P, Davy B. The effectiveness and cost of lifestyle interven- tions including nutrition education for diabetes prevention: a systematic review and meta-anal- ysis. J Acad Nutr Diet 2017;117:404-421.e36</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_FDefswC">Economic evaluation of combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force</title>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.7326/m15-0469</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_U27hsvA">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="452" to="460" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li R, Qu S, Zhang P, et al. Economic evaluation of combined diet and physical ac- tivity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Pre- ventive Services Task Force. Ann Intern Med 2015;163:452-460</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_cHUvhmn">Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Craig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Airoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bevan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Greenhalgh</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2017-017184</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_m6EmEb7">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="17184" to="17203" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. Preventing type 2 diabetes: systematic review of studies of cost-effective- ness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open 2017;7:e017184 19</note>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main" xml:id="_bDmzY4U">Cost-Effective Solutions for the Prevention of Type 2 Diabetes</title>
		<idno type="DOI">10.1002/0470857358.ch2</idno>
		<imprint>
			<date type="published" when="2016">2016</date>
			<publisher>International Diabetes Federation</publisher>
			<pubPlace>Brussels, Belgium</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">International Diabetes Federation. Cost- Effective Solutions for the Prevention of Type 2 Diabetes. Brussels, Belgium, International Diabe- tes Federation, 2016</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_NqS3AGM">Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review</title>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ErX8SdA">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1872" to="1894" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33:1872-1894</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main" xml:id="_KffjAKc">Cochrane Handbook for Systematic Reviews of Interventions</title>
		<idno type="DOI">10.1002/9781119536604</idno>
		<ptr target="https://www.training.cochrane.org/handbook" />
		<editor>Higgins JPT, Thomas J, Chandler J, et al.</editor>
		<imprint>
			<date type="published" when="2019-10-15">2019. 15 October 2019</date>
		</imprint>
	</monogr>
	<note>Internet Version 6.0</note>
	<note type="raw_reference">Higgins JPT, Thomas J, Chandler J, et al. (Eds.). Cochrane Handbook for Systematic Reviews of Interventions [Internet], 2019. Version 6.0. Avail- able from https://www.training.cochrane.org/ handbook. Accessed 15 October 2019</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_BU5ePWW">The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Jefferson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_faK9GmA">BMJ</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="275" to="283" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Drummond MF, Jefferson TO; The BMJ Eco- nomic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submis- sions to the BMJ. BMJ 1996;313:275-283</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<idno type="DOI">10.3886/icpsr08166.v3</idno>
		<ptr target="https://www.bls.gov/cpi/data.htm" />
		<title level="m" xml:id="_9dy2NQ5">Consumer price index</title>
		<imprint>
			<publisher>Medical care in U.S</publisher>
			<date type="published" when="2017-08">August 2017</date>
		</imprint>
	</monogr>
	<note>. city average, all urban consumers, not seasonally adjusted). Accessed 28</note>
	<note type="raw_reference">U.S. Bureau of Labor Statistics. Consumer price index (Medical care in U.S. city average, all urban consumers, not seasonally adjusted). Ac- cessed 28 August 2017. Available from https:// www.bls.gov/cpi/data.htm</note>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main" xml:id="_Rg3yu3a">Board of Governors of the Dederal Reserve System</title>
		<ptr target="https://www.federalreserve.gov/releases/g5a/" />
		<imprint>
			<date type="published" when="2017-08-28">28 August 2017</date>
		</imprint>
	</monogr>
	<note>Foreign exchange rates (G.5A)</note>
	<note type="raw_reference">Board of Governors of the Dederal Reserve System. Foreign exchange rates (G.5A). Accessed 28 August 2017. Available from https://www .federalreserve.gov/releases/g5a/</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_FXRmPRT">What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Braithwaite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Leslie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Roberts</surname></persName>
		</author>
		<idno type="DOI">10.1097/mlr.0b013e31815c31a7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tzxgjEB">Med Care</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="349" to="356" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality- adjusted life-year decision rule? Med Care 2008;46:349-356</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_yCUcprK">Screening adults for pre-diabetes and diabetes may be cost-saving</title>
		<author>
			<persName><forename type="first">R</forename><surname>Chatterjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Narayan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lipscomb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mQrsscs">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1484" to="1490" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chatterjee R, Narayan KM, Lipscomb J, Phillips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care 2010;33:1484-1490</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_Hj7nPC8">Using an economic model of diabetes to evaluate prevention and care strategies in Australia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Colagiuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Walker</surname></persName>
		</author>
		<idno type="DOI">10.1377/hlthaff.27.1.256</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zbZjwGw">Health Aff (Millwood)</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="256" to="268" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Colagiuri S, Walker AE. Using an economic model of diabetes to evaluate prevention and care strategies in Australia. Health Aff (Millwood) 2008;27:256-268</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_YnybRj7">Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Gillies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Abrams</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.39545.585289.25</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7SvgRqH">BMJ</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="1180" to="1185" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008;336:1180-1185</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_eFGPrEy">An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study</title>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gong</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2458-13-729</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WJQJKQd">BMC Public Health</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">729</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu X, Li C, Gong H, et al. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. BMC Public Health 2013;13:729</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_ZwsXUAP">Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling</title>
		<author>
			<persName><forename type="first">A</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lindholm</surname></persName>
		</author>
		<idno type="DOI">10.1186/1478-7547-9-17</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JJvjca7">Cost Eff Resour Alloc</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">17</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Neumann A, Schwarz P, Lindholm L. Esti- mating the cost-effectiveness of lifestyle inter- vention programmes to prevent diabetes based on an example from Germany: Markov model- ling. Cost Eff Resour Alloc 2011;9:17</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_MMzF6np">Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Schaufler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wolff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sXKzNrm">Appl Health Econ Health Policy</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="191" to="202" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 2010;8:191-202</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_TR3try8">The impact of type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Breeze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Squires</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GJTvqVM">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="632" to="640" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Breeze PR, Thomas C, Squires H, et al. The impact of type 2 diabetes prevention programmes based on risk-identification and lifestyle inter- vention intensity strategies: a cost-effective- ness analysis. Diabet Med 2017;34:632-640</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_U8AChPf">Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Selvin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8BTeTHm">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="374" to="381" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhuo X, Zhang P, Selvin E, et al. Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness per- spective. Am J Prev Med 2012;42:374-381</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_8wGTAYe">Costeffectiveness of alternative thresholds of the fasting plasma glucose test to identify the target population for type 2 diabetes prevention in adults aged $45 years</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cZQWNxB">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="3992" to="3998" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhuo X, Zhang P, Kahn HS, Gregg EW. Cost- effectiveness of alternative thresholds of the fasting plasma glucose test to identify the target popula- tion for type 2 diabetes prevention in adults aged $45 years. Diabetes Care 2013;36:3992-3998</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_cQNwsh3">The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/ DPPOS</title>
		<author>
			<persName><forename type="first">Diabetes</forename><surname>Prevention</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Program</forename><surname>Research</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Group</forename></persName>
		</author>
		<idno type="DOI">10.2337/dc13-er12c</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NQFYZcn">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="723" to="730" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes preven- tion: an intent-to-treat analysis of the DPP/ DPPOS. Diabetes Care 2012;35:723-730</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_xW5jgpc">Diabetes Prevention Program Research Group. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Edelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Ratner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rDV3eqr">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="194" to="202" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Herman WH, Edelstein SL, Ratner RE, et al.; Diabetes Prevention Program Research Group. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care 2013;19:194-202</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_fWe7NHc">Medicare&apos;s intensive behavioral therapy for obesity: an exploratory costeffectiveness analysis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hoerger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Crouse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Albright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GCM5Rvm">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="419" to="425" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hoerger TJ, Crouse WL, Zhuo X, Gregg EW, Albright AL, Zhang P. Medicare&apos;s intensive be- havioral therapy for obesity: an exploratory cost- effectiveness analysis. Am J Prev Med 2015;48: 419-425</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_aZRfH46">Cost-effectiveness of SHINE: a telephone translation of the Diabetes Prevention Program</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Hollenbeak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Weinstock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cibula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Delahanty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Trief</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nBJwGek">Health Serv Insights</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="21" to="28" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hollenbeak CS, Weinstock RS, Cibula D, Delahanty LM, Trief PM. Cost-effectiveness of SHINE: a telephone translation of the Diabetes Prevention Program. Health Serv Insights 2016;9:21-28</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_pMhAq5J">Costeffectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let&apos;s Prevent Diabetes cluster-randomised controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Leal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ahrabian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Davies</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2016-013592</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HmHWU6f">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">13592</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leal J, Ahrabian D, Davies MJ, et al. Cost- effectiveness of a pragmatic structured educa- tion intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let&apos;s Prevent Diabetes cluster-randomised con- trolled trial. BMJ Open 2017;7:e013592</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_YQVexYY">Costeffectiveness of the 2014 US Preventive Services Task Force (USPSTF) recommendations for intensive behavioral counseling interventions for adults with cardiovascular risk factors</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bardenheier</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc16-1186</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_s83MZG8">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="640" to="646" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lin J, Zhuo X, Bardenheier B, et al. Cost- effectiveness of the 2014 US Preventive Serv- ices Task Force (USPSTF) recommendations for intensive behavioral counseling interventions for adults with cardiovascular risk factors. Diabetes Care 2017;40:640-646</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_vcECtJC">The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program</title>
		<author>
			<persName><forename type="first">A</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lindholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Norberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schoffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Klug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>NorstrÃ¶m</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10198-016-0851-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QsuzyWb">Eur J Health Econ</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="905" to="919" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Neumann A, Lindholm L, Norberg M, Schoffer O, Klug SJ, NorstrÃ¶m F. The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention pro- gram. Eur J Health Econ 2017;18:905-919</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_Agdv3yn">Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Tucker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aTcbGMB">Prim Care Diabetes</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="109" to="121" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Aus- tralian setting: a long-term modeling analysis. Prim Care Diabetes 2012;6:109-121</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_bZ3YfZM">Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Peels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Hoogenveen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Feenstra</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2458-14-1099</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6vFUr6B">BMC Public Health</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1099</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Peels DA, Hoogenveen RR, Feenstra TL, et al. Long-term health outcomes and cost-effective- ness of a computer-tailored physical activity intervention among people aged over fifty: mod- elling the results of a randomized controlled trial. BMC Public Health 2014;14:1099</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_JrHQCjG">Evaluating the costeffectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Png</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Js-Y</forename><surname>Yoong</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0107225</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vPXwS7A">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">107225</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Png ME, Yoong JS-Y. Evaluating the cost- effectiveness of lifestyle modification versus metformin therapy for the prevention of diabe- tes in Singapore. PLoS One 2014;9:e107225</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_Rgtvgec">Are lifestyle interventions in primary care costeffective?-An analysis based on a Markov model, differences-in-differences approach and the Swedish BjÃ¶rknÃ¤s study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Saha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Carlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U-G</forename><surname>Gerdtham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xHX65Xh">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">80672</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Saha S, Carlsson KS, Gerdtham U-G, et al. Are lifestyle interventions in primary care cost- effective?-An analysis based on a Markov model, differences-in-differences approach and the Swed- ish BjÃ¶rknÃ¤s study. PLoS One 2013;8:e80672</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_cJyqTgM">Peer reviewed: cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern pennsylvania, 2005-2007</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Bryce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Hsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vTgg9eP">Prev Chronic Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">A109</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Smith KJ, Bryce CL, Hsu HE, et al. Peer reviewed: cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovas- cular disease in southwestern pennsylvania, 2005-2007. Prev Chronic Dis 2010;7:A109</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_msndQG4">Economic evaluation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardiovascular diseases: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Van Wier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lakerveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Bot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Chinapaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nijpels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Van Tulder</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2296-14-45</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_68aFPn5">BMC Fam Pract</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">45</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van Wier MF, Lakerveld J, Bot SD, Chinapaw MJ, Nijpels G, van Tulder MW. Economic eval- uation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardio- vascular diseases: a randomized controlled trial. BMC Fam Pract 2013;14:45</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_9dQnCn8">Costeffectiveness of a community-based weight control intervention targeting a low-socioeconomicstatus Mexican-origin population</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><surname>Brown Hs 3rd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bastida</surname></persName>
		</author>
		<idno type="DOI">10.1177/1524839914537274</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cPjefru">Health Promot Pract</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="101" to="108" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wilson KJ, Brown HS 3rd, Bastida E. Cost- effectiveness of a community-based weight control intervention targeting a low-socioeconomic- status Mexican-origin population. Health Promot Pract 2015;16:101-108</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_bXPSWpM">Costeffectiveness of a short message service intervention to prevent type 2 diabetes from impaired glucose tolerance</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F-F</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-C</forename><surname>Siu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2014.08.716</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YwzfUbx">J Diabetes Res</title>
		<imprint>
			<biblScope unit="page">1219581</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong CK, Jiao F-F, Siu S-C, et al. Cost- effectiveness of a short message service inter- vention to prevent type 2 diabetes from impaired glucose tolerance. J Diabetes Res 2016;1219581</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_WJJF4AG">A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Gregg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NGmK5b5">Health Aff (Millwood)</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="50" to="60" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhuo X, Zhang P, Gregg EW, et al. A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years. Health Aff (Millwood) 2012;31:50-60</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_Zqx4uB9">Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups -primary care patients in Sweden</title>
		<author>
			<persName><forename type="first">I</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>HellstrÃ¶m</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Johansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gMsdTpb">Cost Eff Resour Alloc</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">19</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Feldman I, HellstrÃ¶m L, Johansson P. Het- erogeneity in cost-effectiveness of lifestyle coun- seling for metabolic syndrome risk groups -primary care patients in Sweden. Cost Eff Resour Alloc 2013;11:19</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_m6sGwxK">Effectiveness and cost-effectiveness of a cluster-randomized prenatal lifestyle counseling trial: a seven-year follow-up</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kolu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Raitanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Puhkala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tuominen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Husu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Luoto</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0167759</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qPxW62X">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">167759</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kolu P, Raitanen J, Puhkala J, Tuominen P, Husu P, Luoto R. Effectiveness and cost-effectiveness of a cluster-randomized prenatal lifestyle coun- seling trial: a seven-year follow-up. PLoS One 2016;11:e0167759</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_MJdWa7G">Cost-effectiveness of an exercise program during pregnancy to prevent gestational diabetes: results of an economic evaluation alongside a randomised controlled trial</title>
		<author>
			<persName><forename type="first">N</forename><surname>Oostdam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bosmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Wouters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Eekhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Mechelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Van Poppel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UhNuWgh">BMC Pregnancy Childbirth</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">64</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Oostdam N, Bosmans J, Wouters MG, Eekhoff EM, van Mechelen W, van Poppel MN. Cost-effectiveness of an exercise program during pregnancy to prevent gestational diabe- tes: results of an economic evaluation alongside a randomised controlled trial. BMC Pregnancy Childbirth 2012;12:64</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_3SwmFqT">A penny-per-ounce tax on sugar-sweetened beverages would cut health and cost burdens of diabetes</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Coxson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-M</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bibbins-Domingo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EEhuNWM">Health Aff (Millwood)</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="199" to="207" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang YC, Coxson P, Shen Y-M, Goldman L, Bibbins-Domingo K. A penny-per-ounce tax on sugar-sweetened beverages would cut health and cost burdens of diabetes. Health Aff (Mill- wood) 2012;31:199-207</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_N77qyZB">Nutritional policy changes in the supplemental nutrition assistance program: a microsimulation and cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Basu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Seligman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bhattacharya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uK2paFh">Med Decis Making</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="937" to="948" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Basu S, Seligman H, Bhattacharya J. Nutri- tional policy changes in the supplemental nutri- tion assistance program: a microsimulation and cost-effectiveness analysis. Med Decis Making 2013;33:937-948</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_ayPrgV3">Health benefits of reducing sugar-sweetened beverage intake in high risk populations of California: results from the cardiovascular disease (CVD) policy model</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Mekonnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Odden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Coxson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_F7tV25G">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">81723</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mekonnen TA, Odden MC, Coxson PG, et al. Health benefits of reducing sugar-sweetened beverage intake in high risk populations of California: results from the cardiovascular disease (CVD) policy model. PLoS One 2013;8:e81723</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_f4JWCTK">Decreasing the burden of type 2 diabetes in South Africa: the impact of taxing sugar-sweetened beverages</title>
		<author>
			<persName><forename type="first">M</forename><surname>Manyema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Veerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tugendhaft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Labadarios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hofman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fHWTxHZ">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">143050</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Manyema M, Veerman JL, Chola L, Tugendhaft A, Labadarios D, Hofman K. Decreasing the burden of type 2 diabetes in South Africa: the impact of taxing sugar-sweetened beverages. PLoS One 2015;10:e0143050</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_XXxUbEY">Projected impact of Mexico&apos;s sugar-sweetened beverage tax policy on diabetes and cardiovascular disease: a modeling study</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>SÃ¡nchez-Romero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Penko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Coxson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qYJdHrg">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">1002158</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">SÃ¡nchez-Romero LM, Penko J, Coxson PG, et al. Projected impact of Mexico&apos;s sugar-sweetened beverage tax policy on diabetes and cardiovascular disease: a modeling study. PLoS Med 2016;13: e1002158</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_hbkbAub">The impact of a tax on sugar-sweetened beverages on health and health care costs: a modelling study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Veerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sacks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Antonopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Yzf6aT9">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">151460</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Veerman JL, Sacks G, Antonopoulos N, Martin J. The impact of a tax on sugar-sweetened beverages on health and health care costs: a modelling study. PLoS One 2016;11:e0151460</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_szTPgsZ">Costeffectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Breeze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Squires</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2t98cZH">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1136" to="1144" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Breeze PR, Thomas C, Squires H, et al. Cost- effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK. Diabet Med 2017;34: 1136-1144</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_twGkrz9">Taxes and subsidies for improving diet and population health in Australia: a cost-effectiveness modelling study</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Cobiac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Veerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Blakely</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_F7GGEvh">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1002232</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cobiac LJ, Tam K, Veerman L, Blakely T. Taxes and subsidies for improving diet and population health in Australia: a cost-effectiveness model- ling study. PLoS Med 2017;14:e1002232</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_T6p6zSR">Cost effectiveness of subsidizing fruit and vegetable purchases through the supplemental nutrition assistance program</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Seligman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Basu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5HPv8tz">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="147" to="e155" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choi SE, Seligman H, Basu S. Cost effec- tiveness of subsidizing fruit and vegetable pur- chases through the supplemental nutrition assistance program. Am J Prev Med 2017;52: e147-e155</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_5b5azpS">Cost effectiveness of community-based physical activity interventions</title>
		<author>
			<persName><forename type="first">L</forename><surname>Roux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Tengs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cKg77ZB">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="578" to="588" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roux L, Pratt M, Tengs TO, et al. Cost effec- tiveness of community-based physical activity interventions. Am J Prev Med 2008;35:578-588</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_tQcJBCd">Costeffectiveness of interventions to promote physical activity: a modelling study</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Cobiac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Barendregt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eTEj9sc">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1000110</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cobiac LJ, Vos T, Barendregt JJ. Cost- effectiveness of interventions to promote phys- ical activity: a modelling study. PLoS Med 2009;6: e1000110</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_RkET93A">A national effort to prevent type 2 diabetes: participantlevel evaluation of CDC&apos;s National Diabetes Prevention Program</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Ely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Gruss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Luman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aUBb32J">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1331" to="1341" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ely EK, Gruss SM, Luman ET, et al. A national effort to prevent type 2 diabetes: participant- level evaluation of CDC&apos;s National Diabetes Prevention Program. Diabetes Care 2017;40: 1331-1341</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_NP4N92K">Pear R Medicare proposal takes aim at diabetes</title>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pQZ8Nm3">New York Times</title>
		<imprint>
			<biblScope unit="page">12</biblScope>
			<date type="published" when="2016-03-23">23 March 2016</date>
		</imprint>
	</monogr>
	<note>Sect. A</note>
	<note type="raw_reference">Pear R Medicare proposal takes aim at di- abetes. New York Times, 23 March 2016;Sect. A, p. 12</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_jUPFmyG">Women veterans&apos; experience with a web-based diabetes prevention program: a qualitative study to inform future practice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Moin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ertl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y9QjPv2">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">e127</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moin T, Ertl K, Schneider J, et al. Women veterans&apos; experience with a web-based diabetes prevention program: a qualitative study to in- form future practice. J Med Internet Res 2015;17: e127</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_Vfe9v8g">High-tech tools for exercise motivation: use and role of technologies such as the internet, mobile applications, social media, and video games</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Tate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Lyons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Valle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FrKxw8j">Diabetes Spectr</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="45" to="54" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tate DF, Lyons EJ, Valle CG. High-tech tools for exercise motivation: use and role of tech- nologies such as the internet, mobile applica- tions, social media, and video games. Diabetes Spectr 2015;28:45-54</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_qPn2tG5">Potential policy approaches to address diet-related diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krieger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Brownell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7bc9bsW">JAMA</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="341" to="342" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jacobson MF, Krieger J, Brownell KD. Poten- tial policy approaches to address diet-related diseases. JAMA 2018;320:341-342</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_frAfMkg">State preemption of food and nutrition policies and litigation: undermining government&apos;s role in public health</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pomeranz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zellers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pertschuk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rrGxTSc">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="47" to="57" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pomeranz JL, Zellers L, Bare M, Pertschuk M. State preemption of food and nutrition policies and litigation: undermining govern- ment&apos;s role in public health. Am J Prev Med 2019;56:47-57</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_v5JSASc">Sugar-sweetened beverage taxation in the USA, state preemption of local efforts</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pomeranz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pertschuk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WYmyNyP">Public Health Nutr</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">190</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pomeranz JL, Pertschuk M. Sugar-sweetened beverage taxation in the USA, state preemp- tion of local efforts. Public Health Nutr 2019; 22:190</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_yzVMEdW">Sugar-sweetened beverage taxation in 2017: a commentary on the reasons behind their quick spread in the EU compared with the USA</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Hagenaars</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Jeurissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Klazinga</forename><surname>Nsjphn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VPxgSnm">Public Health Nutr</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="186" to="189" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hagenaars LL, Jeurissen PP, Klazinga NSJPhn: Sugar-sweetened beverage taxation in 2017: a commentary on the reasons be- hind their quick spread in the EU compared with the USA. Public Health Nutr 2019;22: 186-189</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_h63WpEP">Prevalence of major behavioral risk factors for type 2 diabetes</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Bullard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Imperatore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CTg2WQQ">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1032" to="1039" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Siegel KR, Bullard KM, Imperatore G, et al. Prevalence of major behavioral risk factors for type 2 diabetes. Diabetes Care 2018;41:1032- 1039</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
